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1. Aim of the project 
The overall aim of the project was to investigate how the preparation and formulation process 
influence the photostability and phototoxicity of respectively a photolabile drug molecule in 
the solid state and a photosensitizer.   
The specific aims of the work were to: 
x investigate the influence of the solid state properties (crystal modification) on the 
photoreactivity of the photolabile drug substance riboflavin (Paper I) 
x evaluate the effect of the type of preparation and excipients on the photodynamic  
effect of the photosensitizer curcumin (Papers II and III) 
x study the effect of the excipients on the interaction of the photosensitizer curcumin 
with a biomolecule (human serum albumin) and the photoreactivity of the 
photosensitizer in biorelevant media (Paper IV). 
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2. Definitions 
A drug substance is an active ingredient contained in a formulated preparation intended to 
provide therapeutic effect directly or indirectly. 
Pharmaceutical formulation is the process of combining different chemical substances, 
including the drug substance (active ingredient) in an appropriate fashion, to produce a final 
preparation. 
A formulated preparation, typically a product of a drug substance and excipients (non-drug 
substances), is made to administrate a drug substance to the body. This term is used 
interchangeably with product, final product, and dosage form throughout this work. 
A photosensitizer (PS) is a light-activated drug substance which, upon absorption of light, 
induces a chemical or physical alteration of another chemical entity. Some photosensitizers 
are employed therapeutically such as in photodynamic therapy of cancer (PDT) or in the 
treatment of bacterial infections (aPDT).  
The photostability of drug substances and products is understood not only as the degradation 
caused by exposure to radiation, but also processes such as radical formation, energy transfer 
and luminescence, within this work. The term is used interchangeable with photoreactivity 
throughout this work.  
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3. Introduction 
The general aim of pharmaceutical formulation work is to achieve safe, efficient, reproducible 
and convenient administration of the drug substance to the body. Excipients are added in 
order to e.g., solubilize, stabilize, suspend, thicken, preserve, emulsify, modify dissolution, 
improve the compressibility or the flavor of the drug substance (1). Excipients, however, need 
to be compatible with the drug substance for the final product to be safe, stable and efficient. 
Most drug substances are white or slightly colored, i.e., they absorb radiation in the UV or 
visible part of the electromagnetic spectrum (2). The photoreactivity of such drug substances 
can be either beneficial or undesirable. In some situations, photoreactivity can be used in 
photoactivated therapeutic systems. Conversely, many drugs are degraded due to exposure to 
visible and UV radiation. We therefore need to control the photoreactivity of drug substances. 
This creates additional complexity during the formulation work. 
The type of preparation and the selected excipients can alter the photostability of the 
photoreactive drug substance (PDS) and affect the efficiency and safety of the final product 
(3-5). Photostability is recognized as an integral part of the stability studies during the drug 
development; photostability testing of the new drug substances and products are addressed in 
the ICH Q1B document of ICH Harmonised Tripartite Guideline (ICH stands for International 
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals 
for Human Use) (6). 
Therapies based on light-activated substances have been established, such as photodynamic 
therapy, PUVA therapy (psoralen based UVA therapy) or drug release via light-sensitive drug 
delivery systems. To maximize the efficiency and safety of such substances or systems, novel 
preparations tailored for (a) the type of condition that is treated, (b) the site of application and 
(c) the therapy protocol, need to be developed.  
The different aspects of the formulation of photoreactive drug substances that will be 
addressed in this work are the photostability of the drug substance in both solid and liquid 
form, preparations specifically designed to combat microbials (aPDT therapy) and 
formulation dependent bacterial phototoxicity, and interaction with human serum albumin 
(HSA). The structure of the thesis in relation to these issues is presented in Figure 1. 
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Figure 1. Structure of the thesis. Roman numerals indicate the number of the papers listed on page 4. The 
papers are grouped according to overlapping subjects. PDS – photoreactive drug substance, SS – solid state, 
PSt – photostability, PS– photosensitizer, Ex – excipients. 
Riboflavin was selected as the model substance for examining the influence of the 
formulation on the photostability of a solid state PDS. This substance is usually included in 
vitamin dietetic supplements and its photoreactivity poses a great challenge for the 
formulation of the final product (7). Curcumin was studied as a model of a small, lipophilic 
photosensitizer (PS).The photodynamic antimicrobial activity of curcumin has been 
demonstrated in vitro, however its application is limited by unfavorable physico-chemical 
properties of the compound (8). Tailor-made pharmaceutical formulations could overcome 
these obstacles and facilitate clinical use of this PS. Human serum albumin was selected as a 
model protein to study interaction with the PS (curcumin) and the influence of excipients on 
this interaction. 
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3.1 Photoreactivity of the drug substance 
No photochemical or subsequent photobiological reaction can occur unless electromagnetic 
radiation is absorbed, according to the First law of photochemistry postulated by Grotthus and 
Draper (9). The ability of a drug substance to absorb radiation is the first indication that a 
substance may be capable of participating in photochemical and photobiological processes. 
The most important chemical outcome of the absorption of UV-Vis radiation is the transition  
 
 
 
Figure 2. The routes to dissipation of excitation energy. D is the drug substance, D* is the drug substance in 
an electronically excited state and hν is electromagnetic radiation (hν’ and hν’’ are photons emitted via 
fluorescence and phosphorescence, respectively), M is an acceptor molecule and M† is an acceptor 
molecule in an electronically excited state. The symbols *, ** and † indicate excited states, but not the 
specific quantum state.   
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of an electron from an orbital in the ground state into a higher energy orbital resulting in an 
electronically excited-state. The molecule in its excited state can exhibit a dramatically 
different reactivity from the ground state, not only because it possesses excess energy but also 
as a result of the new electronic arrangement (10). The energy associated with radiation in the 
UV-Vis region is of the same magnitude as certain bond energies and thus electronic 
excitation can cause photochemical degradation of the compound. Furthermore, the absorbed 
energy can be transferred to other, non-absorptive molecules (e.g., oxygen) as in 
photodynamic therapy. The resulting products are usually chemically distinct from the 
thermal degradation products of the drug molecule. Excess energy can also be lost by several 
other radiative or non-radiative routes (Fig. 2). As a result of intersystem crossing and 
intermolecular energy transfer, new excited electronic states can be formed that can take part 
in the processes shown in the diagram (Fig. 2).  
3.1.1 Direct and indirect photoreactions 
Direct photoreactions 
Absorption of UV-Vis radiation may lead to chemical changes of the drug substance, i.e., 
reactions in which the reactant and products differ in chemical identity rather than in their 
state of excitation. This process is referred to as a direct photoreaction. 
The reactivity of the molecule in an excited state is governed by the excess energy it 
possesses, the intrinsic reactivity of the electronic arrangement and the relative efficiencies of 
the different competing pathways for loss of the excess energy (9, 11).  Therefore, even if the 
drug substance absorbs radiation strongly, a direct photoreaction is less likely to occur if it 
fluoresces or efficiently transfers the energy to another molecule present in the preparation. 
The excited state of the molecule can exhibit markedly altered chemistry compared to the 
molecule in the ground state, as mentioned above. Bond lengths, bond orders and bond angles 
in excited state molecules may be considerably different from their corresponding ground 
states as a consequence of the redistribution of the electron density (10). 
Indirect photoreactions (photosensitized reactions) 
In the case of an indirect or sensitized photoreaction there is a transfer of excitation energy to 
a molecule other than the compound which initially absorbs the radiation. The compound that 
absorbs the radiation, the photosensitizer, is initially transformed from its ground state (singlet 
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state) into a relatively long-lived excited triplet state via a short-lived excited singlet state (Fig. 
2, Intersystem crossing; Fig. 3). The excited triplet state can mediate a photosensitized 
reaction due to the long lifetime and bi-radical nature with unpaired electron spins (11). In the 
type I photosensitized reactions the sensitizer can transfer an electron, including simultaneous 
transfer of a proton corresponding to the transfer of a hydrogen atom, to the molecules in its 
vicinity resulting in a free radical reaction. Energy transfer from the excited triplet state of 
sensitizer to the spin-matched oxygen in the ground state leads to the formation of excited 
singlet oxygen. This process is regarded as type II photosensitized reaction (Fig. 2, 
intermolecular energy transfer; Fig. 3) (12). During the energy transfer process the PS is 
simultaneously brought back to its singlet ground state where it in principle can take part in 
further sensitization cycles (13). 
3.1.2 Outcome of the photoreactivity of the drug substance 
Outcome of the photoreactivity on in vitro stability and adverse drug reactions in vivo 
The photodecomposition of a large number of drug molecules in both the solution (14) and 
the solid state (15) has been reported. Loss of the potency can occur as a result of in vitro 
instability, leading to inactive products. Furthermore, PDS degradation may lead to adverse 
drug reactions due to formation of degradation products during storage (2). However, the 
inherent photoreactivity of the drug substance is not the only factor determining the storage 
stability of the final product. The substance will only degrade if it comes in contact with 
radiation of an appropriate wavelength. The overlap of the absorption spectrum of the drug 
substance with the spectral output of the incident light is described as the overlap integral, and 
it determines the rate of the photoreaction (11, 16). Basic understanding of photoreactivity of 
the compound is required to provide information for handling, packaging, labeling and use of 
the drug substance and the final product. In most of the cases suitable packaging provides 
adequate protection for PDS. However, sometimes a modification of the preparation must be 
considered.  
The in vivo light-induced interactions of the drug substance with endogenous substrates can 
lead to adverse photosensitivity effects. Phototoxicity, one type of photosensitivity effect, is 
defined as an alteration of cell function by an interaction between the phototoxic compound 
and nonionizing radiation. A phototoxic effect can only occur if the drug substance or the 
phototoxic metabolite is distributed near the body surface (e.g., the eye, skin, hair or 
10 
 
outermost capillaries of the skin) and the absorption spectrum of the drug overlaps with the 
transmission spectrum of light through the tissue (17).  
Therapeutic aspects of the drug substance photoreactivity  
The ability of some compounds to cause phototoxicity in vivo is utilized in photodynamic 
therapy (PDT). This is a treatment modality that combines a PS and radiation of appropriate 
wavelength to treat a number of conditions e.g., cancer, age-related macular degeneration, 
actinic keratosis, psoriasis, and localized inflammations (especially rheumatoid arthritis) (12). 
PS can be applied parenterally (e.g., therapy of cancer and age-related macular degeneration) 
or locally (e.g., therapy of actinic keratosis, psoriasis, localized inflammations and infectious 
diseases). Upon absorption of radiation, the PS can undergo a type I or type II photosensitized 
reaction. Following the type I reaction it can react directly with endogenous substrates 
forming radicals. These radicals can react further with oxygen to produce reactive oxygen 
species (ROS). Alternatively, the type II reaction involves a direct interaction between the 
excited PS and the ground state oxygen resulting in singlet oxygen formation. Type I and type 
II reactions occur simultaneously, and the ratio between these processes depends on the type  
 
Figure 3. Simplified Jablonski diagram of the pathways leading to photosensitization following application 
of radiation to a PS. When a PS absorbs radiation it may undergo an electronic transition from the ground 
state (1PS0) to the first singlet excited state (1PS1*). Some of the molecules are transferred to the triplet state 
(3PS1*) via intersystem crossing. The triplet state is lower in energy than the singlet state, and some energy 
is lost in the process. The charge (type I reaction), or energy (type II reaction) may be transferred from PS 
to a substrate or to molecular oxygen (in a triplet state, 3O2), to generate reactive oxygen species (ROS) or 
singlet oxygen (1O2) respectively. Adapted from (18). 
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of sensitizer used, the concentrations of substrate and oxygen, as well as the binding affinity 
of the sensitizer for the substrate (12). The ROS and singlet state oxygen can kill microbial or 
cancer cells by inflicting damage on biomolecules such as proteins, unsaturated lipids, 
steroids and nucleic acids (Fig. 3).  
Antimicrobial photodynamic therapy 
PDT applied in the treatment of microbial infections is termed antimicrobial photodynamic 
therapy (aPDT).  The delivery of the radiation to living tissue is a localized process and 
therefore aPDT is limited to localized as opposed to systemic infections (19). Furthermore, 
due to the limited penetration depth of radiation through the tissue, aPDT is mostly applied at 
areas of the body where radiation can be easily delivered (20). However, with the progress in 
optical fibre technology even deep-seated infections could potentially be treated by aPDT (21). 
The therapy is gaining increasing attention owing to the rise of microbial resistance to the 
major families of antibiotic compounds (18). Many antibiotic-resistant microbial strains have 
shown to be susceptible to aPDT due to the substantially different pathways of inactivation 
compared to that of the antibiotic and chemotherapeutic agents. No selection of the 
photoresistant species occurred even after multiple treatments (18, 19, 21, 22). A comparison 
of some of the main advantages and disadvantages of the treatment with traditional 
antimicrobial drugs and aPDT are presented in Table 1.  
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Table 1. Comparison of treatment with traditional antimicrobial drugs and antimicrobial photodynamic 
therapy (aPDT) (18, 19, 21-24). 
Traditional antimicrobial 
drugs 
aPDT 
Targets 
Typically one type of 
biomolecule 
Large variety of  biomolecules (multi-
targeted process) 
Resistance 
Occurs and is not limited to 
targeted pathogens 
Not likely to develop due to the multi-
targeted nature of the process 
Spectrum of 
action 
Typically efficient against 
one or two pathogen types 
Typically broad spectrum of action: 
bacteria, fungi, yeasts and parasitic 
protozoa 
Effect on 
virulence factors 
Typically no effect on 
virulence factors  
Reduction of virulence potential of 
bacteria 
Routes of 
application 
Oral and topical; applicable 
for localized and systemic 
infections 
Topical; mostly applied for localized  
infections  
Side effects 
Many, including allergies 
and intestinal disorders 
Limited side effects (due to a dual 
selectivity: PS can be targeted to 
microbial cells, radiation can be spatially 
directed to the lesion)  
Effect of protein binding on therapeutically applied photoreactions and phototoxicity  
Binding of the drug substance to blood and tissue proteins can influence its therapeutic and 
toxic action. Protein binding may strongly affect the biodistribution of the drug substance. 
The complex with protein acts as a transporter system to carry the drug substance to the site 
of action; this transport is extremely important for substances with low solubility in the 
aqueous portion of the plasma (25). The bound molecules however, cannot readily leave the 
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capillaries. Only the unbound molecules can be distributed to tissues and exhibit 
pharmacological activity as well as toxic effects. Thus, depending on the drug substance and 
the target, the high affinity for plasma proteins may be either beneficial or a drawback for 
efficacy (26). Binding to plasma proteins also affects metabolism and elimination, since both 
hepatic uptake and glomerular filtration are directly proportional to the free drug molecule 
fraction present in the plasma (25, 26).  
The factors that can affect binding of drug substance to plasma proteins are concurrent 
administration of other drugs, excipients in the preparation, pathological conditions, age, and 
sex (26).  
Phototoxicity is dependent upon the concentration of the sensitizer and the overlap integral 
between the sensitizer and the incident radiation at the site of action. Therefore, a prerequisite 
for the phototoxic reaction to occur is that the drug substance with sensitizing properties is 
distributed to the tissues that are exposed to radiation (17). Drug substances highly bound to 
plasma proteins usually have low apparent volume of distribution (Vd) because they are 
confined to the vascular space. Conversely, substances that are largely free in plasma are 
generally available for distribution to tissues. However, some substances that are highly 
bound to plasma proteins are bound with greater affinity to tissue proteins, resulting in a large 
Vd value. The distribution of a drug substance is a function of both plasma protein binding 
and tissue protein binding (26). Prolonged phototoxicity can be expected as the result of 
delayed elimination of the drug substance with photosensitizing properties if the substance is 
highly bound to plasma proteins.  
The effect of the PS affinity for plasma proteins on the efficiency of photodynamic therapy 
depends upon the route of administration and the target tissue. Following parenteral 
administration PS needs to be delivered to the target tissue prior to exposure to radiation. 
Pharmacokinetics and biodistribution of PS can vary greatly among the different types of 
photosensitizers (27). These parameters can be influenced by the plasma protein binding as 
discussed above. Moderate binding to the plasma proteins can promote distribution of PS in 
the body whereas a high binding affinity may result in prolonged skin phototoxicity (28). The 
interval between parenteral PS administration and radiation exposure needs to be adjusted 
according to pharmacokinetic properties of PS to secure PDT efficacy (27).  
14 
 
When the PS reaches the target tissue it can be further influenced by the interaction with 
plasma proteins. Binding to the plasma proteins have been correlated to both increased (29) 
and decreased (30) uptake by the target cells. The PS-protein interaction often affects the 
equilibrium between monomeric and aggregated species which is particularly important for 
porphyrins and phthalocyanines. The interaction can promote monomerization or support self-
assembling (31). Binding-induced aggregation is not a desirable process since it leads to 
decrease in photodynamic efficiency. Binding can alter the photophysical and photochemical 
properties of PS. Generally, type I reactions are more likely to occur in the presence of 
proteins and many PS are photodegraded much faster in medium rich in proteins or amino 
acids (32). The absorption spectrum of PS (porphyrines) bound to proteins can significantly 
deviate from the corresponding monomer in an aqueous solution. The spectral effects are due 
to the altered microenvironment of PS – the polarity of the protein environment is lower than 
that of water (31). The lifetime of the triplet state of PS bound to proteins recorded in the 
absence of oxygen is much longer than the corresponding lifetime of the free molecules in 
solution. However, production of singlet oxygen and ROS competes with other photophysical 
and photochemical processes in the PS-protein complex (31). It has been suggested that 
human serum albumin removes singlet oxygen from the sensitizing system. Sole binding of 
the PS should not affect the generation of ROS under the condition that the PS does not 
aggregate or is not bound close to protein constituents that quench the excited states 
(electron/energy transfer processes) (31). The photostability of PS generally decreases in the 
presence of proteins (33) and amino acids (34) compared to pure buffer.  
The influence of physiological conditions on aPDT efficiency has been studied in vitro using 
biological materials and ex vivo (19, 35). Proteins present in the medium typically protect 
microorganisms towards aPDT (36-38). However, the actual impact of the protein rich media 
on the aPDT effect was shown to be dependent both upon the type of PS and microorganism 
(38, 39).  
The following factors have been suggested as the cause of the observed effect of the proteins 
on the photokilling of microorganisms (37): 
x proteins may absorb light and reduce the number of photons available to interact with 
PS molecules thereby reducing the production of ROS  
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x proteins may compete with the microorganisms for PS, decreasing the number of PS 
molecules available to interact with target microorganisms  
x ROS have short lifetimes and, unless generated in close proximity of the cells would 
be unlikely to produce any cytotoxic effect. Accordingly, proteins may protect 
microorganisms from cytotoxic species generated in the supernatant. The culture 
medium has also been reported to quench singlet oxygen and free radicals produced by 
PS 
PS bound to protein is therefore trapped and unavailable to interact with microorganisms 
while the ROS produced by exposure to irradiation may more easily be quenched by proteins 
complexed with PS. Moreover, direct reaction of plasma proteins with the photosensitizer 
methylene blue was proposed as a reason for bleaching of the PS, low singlet oxygen yield, 
and consequently the low photoinactivation of bacteria in plasma (40). On the other hand, 
some of the products formed in photodynamic protein oxidation can sustain chain reactions 
and therefore be highly detrimental to cells (28). This mechanism could explain the recently 
reported improved aPDT effect of toluidine blue in serum and human serum albumin solution 
compared to the buffer medium (41). 
3.2 Formulation of photoreactive drug substances 
Formulation of the PDS can be viewed from the two main points:  
x the influence of the formulation on the photostability of the PDS 
x the effect of the formulation on the efficiency of the light-activated drug substance  
3.2.1 Influence of the formulation on the photostability  
Most photochemical reactions are affected by the immediate environment of the reacting 
molecule. Therefore, both the excipients and the type of preparation could influence the 
photoreactivity of the drug substance.  
Solid preparations  
In the solid state (e.g., tablets, capsules, powder) the photochemical process takes place at the 
surface of the dosage form. In most cases the interior of the preparation will be unaffected, 
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independent of exposure time (3). Therefore, photostability of PDS in a solid dosage form is 
not only dependent on the photochemistry of the substance in the given environment, but also 
on factors that will influence the depth of the light penetration, i.e., change in the absorption 
and reflection at the surface (e.g., particle size, shape and surface properties, color, thickness 
of powder bed, coating of the individual particles or dosage form) (42). Furthermore, if the 
photoreaction of the active ingredient results in products that are strong absorbers, only a 
limited overall reaction will occur (4, 15).  
Crystal modification and lyophilization 
The photodegradation rate of the substance as a dry powder, in addition to the above listed 
factors, can be affected by the physical form of the substance (crystalline or amorphous form) 
and the presence of impurities (3, 4). Common practice in drug development is to prepare 
several different crystal modifications and amorphous forms and identify the one with the 
most suitable properties, mainly related to bioavailability and stability. Photostability of the 
different crystal forms have been shown to vary greatly (43, 44). The factors that can govern 
photoreactivity of a substance in the solid state are specific inter- and intramolecular bonds 
(characteristic for each crystalline form), differences in diffusability (crystalline vs. 
amorphous form) and differences in water content (crystal water, adsorbed water) (3).  
The factors that can influence the photostability of freeze dried products are the physical state 
of the substance, porosity, surface properties and the presence of residue solvent. Although 
both poor (45) and satisfactory (46) photostability of PDS in the freeze dried state have been 
reported, no comparison to the non-lyophilized drug substance was provided and therefore it 
is hard to determine actual influence of the lyophilization. Chongprasert et al. have shown 
that different crystalline forms of the drug substance were obtained depending upon 
lyophilization parameters which resulted in different photostability of the products (44). 
Tablets (compressed dosage forms) 
Aman and Thoma (4) used tablets containing the highly photosensitive drug substances 
nifedipine or molsidomine to investigate the influence of the formulation and tableting 
processes on the photostability of the products. Granulation can induce destabilization of the 
PDS if the substance is soluble in the granulation fluid. A residue of the granulation fluid 
present in tablets can cause partial dissolution of the substance and lead to increased 
17 
 
degradation (4). Even if the degradation is not increased, the dissolution and recrystallization 
of the active ingredient can lead to altered photoreactivity. Therefore, the authors suggested 
use of the direct compression method if the drug substance is soluble in the granulation fluid. 
Furthermore, high porosity caused by low compression forces did not promote 
photodegradation in the selected drug substances. Conversely, a relative increase in active 
ingredient content in the surface regions caused by high compression forces, led to more drug 
substance being exposed and degraded. The authors proposed that high compression forces 
should be avoided (4).   
The physical state of the drug substance can influence the photostability of the tablets as 
discussed above. The production method of the bulk substance may therefore determine the 
photostability of the final product. Furthermore, any change in the physical state of the drug 
substance introduced by formulation can lead to altered photoreactivity of the final product. 
The particle size of the bulk substance has been shown to have significant influence on the 
photostability of the drug powders themselves but not of the tablets (4). 
Formulation methods commonly employed to modify solubility and dissolution rate of active 
ingredients can interfere with the overall photostability of the product. Micronization of raw 
materials using milling techniques can cause a change in crystalline form or amorphization of 
the substance, which may alter its photoreactivity (3). Dispersions of drug substance in a 
carrier can have either a stabilizing or destabilizing effect depending upon the level of 
dispersion of active ingredient (as molecules or particles), physical state of the compound, 
transparency and sensitizing properties of the carrier, and mobility of the active ingredient in 
the solid dispersion (3). 
The excipients, due to dilution and other possible shielding effects, usually decrease the effect 
of radiation. However, some excipients may act as photosensitizers and decrease 
photostability (15). Conversely, addition of a quencher (substance that can react with any 
photochemical intermediates ideally to produce harmless products) can stabilize PDS against 
the radiation (9). 
Cyclodextrins (CDs) are cone shaped oligosaccharides, used for increasing stability and water 
solubility of drug substances by forming water-soluble complexes (47). Although there are 
reports of increased photostability of the drug substances by CDs in the solid state, it is not 
always clear whether the inclusion of the molecules in the CD cavity or simply dilution in a 
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physical mixture brings upon photostabilization (15). The photochemistry and photophysics 
within the CD cavity can be quite different from those of the uncomplexed substances. The 
interior of the cavity represents an isolated environment where the included substrates are 
usually present as single molecules restricting the photochemistry to intramolecular events. In 
some cases complexation with CDs can increase photodegradation. This would be likely if the 
guest molecule was only partially included in the CD cavity with the photosensitive region of 
the molecule exposed (15).  
Photodegradation, one of the most obvious outcomes of the molecules’ photoreactivity, may 
lead to the loss of potency or adverse effects caused by decomposition products. Interaction 
with light may also result in the modification of physico-chemical properties, usually fading 
or discoloration of solid state preparations. The change in appearance is not only of aesthetic 
concern. Even if this is not correlated to decomposition and loss of activity it can lead to 
reduced compliance and discarding of qualitatively sound products. 
Liquid preparations  
Photoreactivity of the substances in solution may largely differ from that observed in the solid 
state and is generally more pronounced (4, 15). Secondary reactions of primary photoproducts 
with the solvent (typically water) can result in the formation of species that are not possible in 
the solid state (15). In samples containing the drug substance at a high concentration (i.e., 
high absorbance) the drug molecules in the inner volume of a sample will be protected from 
irradiation due to absorption of most of the radiation by outer layers of the solution (close to 
the sample surface). As a result of this process, termed inner filter effect, concentrated 
solutions of PDS will apparently undergo less photodegradation than diluted samples of the 
same compound. This may cause severe problems in formulation and application of parenteral 
preparations which typically contain the drug substance in a low concentration (42).  
Buffers, tonicity adjusters, preservatives, bulking agents and protectants commonly present in 
parenteral preparations can influence photostability of the active ingredient by a number of 
mechanisms (5). Buffers and tonicity adjusters can influence solvation of the molecular 
ground or excited state leading to altered absorption of radiation or altered reactivity. 
Additionally, some salts are able to complex the drug substance. Interaction between 
primaquine and citrates is suspected to be the reason for photostabilization of the substance in 
citrate buffer (5). The amino acid histidine is used as a bulking agent in lyophilization and can 
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serve as part of the buffer system and stabilizer. Histidine is a quencher of singlet oxygen and 
a scavenger of hydroxyl radicals and can therefore contribute to the overall photostability of 
PDS in solution (5). Methyl paraben, one of the commonly used antimicrobial preservatives, 
has been shown to decrease the photodegradation of riboflavin phosphate in solution, 
probably acting like a radical scavenger (48). Antioxidants can be included in the preparations 
to protect the active ingredient or excipients from oxidation, if other means cannot be applied 
(e.g., purging of the preparation by inert gas) (5). Metabisulfite is an antioxidant used in 
aqueous parenteral preparations. Photochemical decomposition of epinephrine was found to 
be accelerated by metabisulfite (5). The reaction has a complex pathway and includes the in 
situ formation of a photosensitizer by thermal (dark) reaction in the epinephrine infusion 
solutions (5). 
Cosolvents and surfactants affect the photoreactivity of the active ingredient by changing the 
polarity of the reaction medium or increasing the solubility of the drug substance and thus 
changing the absorption properties of the compound or preparation (42). 
Complexation with cyclodextrins and encapsulation in micelles are some of the common 
approaches for solubilization of drug substances suffering from poor water solubility. The 
steric constriction and microenvironment of molecules included in the cavity of CDs (e.g., 
polarity, specific interactions, presence of oxygen) will influence the excited state and 
deactivation pathways (3). Photostabilization of active ingredients by complexation with CDs 
has been reported in many cases. However, a destabilizing effect can also occur (3). Micellar 
systems consist of agglomerates of amphiphilic macromolecules with a hydrophobic core and 
a hydrophilic corona. Hydrophobic compounds can be solubilized in aqueous media by 
incorporation in the micellar core. Micelles can alter the photoreactivity of the drug 
substances due to changes in microenvironment (e.g., polarity, viscosity), molecular 
orientation as well as charge and redox properties. Furthermore, upconcentration of reactant 
within a small volume occurs within the micellar core. This can lead to stabilization or 
destabilization of the drug molecules (3).  
3.2.2 Formulation of products intended for aPDT 
The ideal drug delivery system for aPDT should provide selective accumulation of the PS in 
the target tissue, and more specifically in the target cells, with little or no uptake by non-target 
cells. The carrier should not cause loss or alternation of PS activity, and it should preferably 
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be biodegradable and have little or no immunogenicity. Most PSs suffer from high 
hydrophobicity and thus the delivery system should facilitate interaction with the aqueous 
environment. Further, the PS should be delivered in a monomeric state as aggregation of the 
molecules can decrease ROS production and thereby PDT effect (49). In oncological PDT the 
PS or its precursor is administrated intravenously and accumulated in target tissues owing to 
disordered metabolism and blood flow peculiar to neoplastic tissue. Targeting of the PS to 
sites of infection cannot be achieved by the same mechanism and the PS must be applied 
topically (50). The uptake by microbial cells occurs in a nonspecific manner (i.e., not 
mediated by a photosensitizer-specific uptake mechanism). Selectivity of aPDT therefore 
mainly relays on a more rapid uptake of PS by microbials than by the human cells (18). The 
combination of a short incubation time, low PS concentration and a low irradiation dose is 
desirable since it allows a selective killing of microbial pathogens under conditions in which 
human cells (e.g., fibroblasts or keratinocytes) are spared (51). Delivery systems with a fast 
release of the active ingredient immediately available for interaction with the pathogens are 
required to allow for a short incubation time. Furthermore, the site of action may pose specific 
demands on the formulation of the PS. Preparations aimed to be used in the oral cavity should 
be able to withstand an aqueous environment, proteins including enzymes and mechanical 
stress without degradation or removal.  For the delivery to dry wounds a moist environment is 
essential for the PS to reach the target. In some cases the temperature and pH may also affect 
the release of the PS from the preparation (20). The protein content depends upon the site of 
action (e.g., wounds vs oral cavity), the state of infection (chronic vs acute infection) and type 
of microorganisms. Although proteins typically protect microorganisms towards aPDT, this 
effect may be moderated by selection of appropriate excipients in the preparation as discussed 
in section 3.2.3. Finally, stability of the preparation and the ease of application are important 
for clinical use of PS. The preparation should not influence the penetration depth/intensity of 
the radiation due to scattering. If this is the case the drug delivery system must be removed 
prior to irradiation (50).  
Supersaturated solutions 
Only PS molecules which are bound to the cells are effective in promoting phototoxic effect 
due to the short life time and high reactivity of ROS (52). Therefore, the delivery system for 
antimicrobial PS should provide sufficient interaction between the microbial cell wall or 
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plasma membrane and the PS. Passive diffusion of the molecule can be assessed in the 
context of Fick’s First low (53) 
J = - D dc/dx (1) 
where J is the flux of the molecule across a plane of unit area, D is the diffusion coefficient of 
the molecule and dc/dx is the concentration gradient. The rate of transfer, for example uptake 
of PS in the microbial membrane per unit area and time is proportional to the concentration 
gradient at the membrane surface. For a poorly water soluble PS a low concentration at the 
membrane surface can limit the uptake. However, the concentration of the substance does not 
have to be limited by its equilibrium solubility. Solutions containing the drug substance in a 
concentration exceeding its equilibrium solubility are known as supersaturated solutions. 
Higuchi has first recognized the potential of supersaturation as a mean of enhancing the 
transport of a drug substance across a biological membrane (54). Compared to conventional 
solubilizing strategies, e.g., incorporation of the drug molecule into colloidal species or 
complexing agents, a supersaturated solution possesses a higher free drug substance 
concentration which may create an enhanced driving force for the uptake (55).  
A higher energy form of the drug substance (compared to crystalline form) is required in 
order to generate a supersaturated solution. Some of the approaches include cosolvent systems 
and lipid-based formulation for the delivery of the substance in the solution or production of 
high energy solid forms (e.g., amorphous forms, crystalline salts, co-crystals). Supersaturation 
is a thermodynamically unstable state and therefore prone to precipitation. Supersaturated 
solutions need to be kinetically stabilized to be useful, i.e., precipitation needs to be 
temporarily inhibited.  
Precipitation inhibition 
Precipitation from supersaturated solutions consists of two steps - nucleation and crystal 
growth (56). Although precipitation is a thermodynamically preferred process, the nucleation 
step requires activation energy. As long as this energy barrier is not overcome, the metastable 
state of supersaturation is maintained (57). Once the nucleation is initiated, nuclei can grow to 
macroscopic crystals. The crystal growth follows two stages: the diffusion of molecules from 
the supersaturated solution to the crystal interface and integration into the crystal lattice which 
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is accompanied with desolvation. Precipitation inhibitors (PI) are excipients that can interfere 
with the nucleation and/or crystal growth and delay the precipitation from the supersaturated 
solution. PI may act by one or more of the following mechanisms (57): 
x increasing the solubility and thus reducing the degree of supersaturation (decreasing 
both nucleation and crystal growth) 
x increasing the viscosity (decreasing both nucleation and crystal growth) 
x increasing nucleus-liquid interfacial energy (decreasing nucleation) 
x changing the adsorption layer at the crystal-medium interface (e.g., by adsorbing onto 
the crystal surface) and hindering crystal growth 
x changing the level of solvation at the crystal-liquid interface and affecting the 
integration of molecules into the crystal lattice 
The capacity of PI to inhibit precipitation of the drug substance depends on the properties of 
the inhibitor, the drug substance and the medium and typically needs to be assessed for each 
system.  
Solid dispersion 
A supersaturated state of the substance can be achieved by dissolving a solid dispersion (SD) 
of the substance in aqueous medium. SDs aim to generate a supersaturated solution of poorly 
soluble substances by increasing apparent solubility and/or dissolution properties (57). The 
increase in dissolution rate and apparent solubility are achieved through reduction of the 
particle size, improved wetting, reduced agglomeration, changes in the physical state of the 
substance and possible dispersion at the molecular level (58). Change of the physical state i.e., 
conversion of the crystalline form to the amorphous form enhances the release of the drug 
substance because no energy is required to break up the crystal lattice during the dissolution 
process (59).  
The carriers commonly used in the formulation of SDs are polyethylene glycol (PEG), 
polyvinylpyrrolidone (PVP), polyviniyl alcohol, hydroxypropylmethylcellulose (HPMC), 
hydroxypropylcellulose, carboxymethylethylcellulose , polyacrylates, polymethacrylates, urea, 
sugars and their derivatives, emulsifiers and others (58, 60).  
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3.2.3 Influence of excipients and type of preparation on protein-PDS interaction 
The binding affinity of a drug molecule to plasma protein (bovine serum albumin-BSA) has 
previously been found both to increase or decrease in the presence of micelles, depending on 
the model drug substance, when the substances were delivered from micellar form of the 
surfactant (61). The same study showed that the micellar solution did not affect the integrity 
of the binding site. In another study it was shown that increased protein concentration resulted 
in decreased stability of polymeric micelles, although micellar stability could not be linked to 
protein adsorption to micelles (62).  
Published in vivo studies have indicated that formation of drug substance-CD complexes have 
negligible effect on drug pharmacokinetics (63-65). Kurkov et al. (66) have studied 
competitive binding of drug substances between CDs and HSA in vitro and concluded that the 
molecules with high affinity for both HSA and CD are likely to be affected by parenterally 
administered CD. Application of CDs was suggested as a mean for photostabilization (both in 
vitro and in vivo) and the decrease of phototoxicity of drug substances due to the observed 
altered photoreactivity of the PDS-CD complexes compared to uncomplexed molecules (67). 
There is the clear evidence that CDs do suppress the photosensitizing power of some PDS 
(68). However, Partyka et al. (69) have shown in an appropriate in vitro model that due to the 
displacement of the drug substance from CD complexes by plasma proteins, considerably 
weaker complexation with CDs can be expected in vivo. Reduction in phototoxicity cannot be 
attributed solely to the ability of the CD to complex the drug molecules. The inhibition of 
phototoxicity may be due to CD complexation of toxic photoproducts and trapping of radical 
species formed during photolysis (69).  
Delivery vehicle can affect both the distribution of the substance and the availability at the 
site of action (i.e., bound to plasma proteins or to the delivery vehicle). The overall outcome 
depends on the model substance, the excipients and the type of preparation (e.g., monomeric 
surfactants vs micellar solution). Understanding the effect of the delivery system on the 
protein-drug substance interaction, combined with information about the outcome of the 
protein binding on the final effect (e.g., distribution in the body, target cell uptake, 
photoreactivity of the molecule in the bound state etc.) can help to create a delivery system 
with improved efficiency and decreased toxicity. 
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3.3 Model photoreactive drug substances 
3.3.1 Riboflavin as model of a photolabile drug substance 
Riboflavin (vitamin B2) is part of the vitamin B group and a frequent ingredient of dietary 
supplements. It belongs to the group of compounds known as flavins, based on nitrogen 
heterocycle 7,8-dimethylisoalloxazine (Fig. 4). Riboflavin is a yellow-orange powder that can 
be produced either synthetically or by a fermentation process.  
Biological roles of flavins and therapeutic application of riboflavin  
Flavins play an important role in aerobic metabolism due to their ability to catalyze two-
electron dehydrogenation of numerous substrates and to participate in one-electron transfer to 
various metal centers through their free radical states (70). Flavins are cofactors for a variety 
of enzyme systems, such as succinate and NADH dehydrogenases, xanthine 
oxidase/dehydrogenase, cytochrome P450 system and nitric oxide synthase (70).  
Riboflavin deficiency studied in animals resulted in reduced growth and a great variety of 
lesions including changes in the skin, loss of hair, degenerative changes in the nervous system 
and liver, impaired reproduction, and congenital malformations in offspring (71). Subclinical 
riboflavin deficiency in humans may be associated with an increased risk of cardiovascular 
disease, impaired handling of iron and night blindness (72).  
The main source of riboflavin in Western diets is milk and dairy products. High 
concentrations of riboflavin can also be found in cereals, meats and fatty fish, and in certain 
fruit and vegetables (72). Riboflavin deficiency is endemic in populations who exist on diets 
lacking dairy products and meat (72). Riboflavin is widely used as vitamin supplement, 
colorant and additive in food.  
Photochemical reactions of flavins  
Photoreactivity of riboflavin in pharmaceutical products (73), parenteral nutrition admixtures 
(74-76) and food products (77), as well as photostabilization of the substance (48, 78, 79) 
have been the subject of extensive investigation. The focus of the present work was a specific 
problem which occurred after a change in production method of the riboflavin bulk substance 
was introduced. A switch between two qualities of bulk material (i.e., from synthetic to 
Ϯϱ
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biosynthetic riboflavin) induced a decrease in the photostability of riboflavin tablets. Severe 
discoloration was observed after inadvertent exposure to light, although the tablets were 
quantitatively sound (80). Investigations revealed that a particular photoreactivity of the 
biosynthetic bulk material caused a decrease in photostability of the tablets (81). A thorough 
understanding of the reaction mechanism was needed in order to reformulate and stabilize 
tablets containing biosynthetic riboflavin. 
Figure 4. Structure of riboflavin 
The absorption spectrum of riboflavin in aqueous solutions consists of four structureless 
peaks centered at 446, 375, 265 and 220 nm.  
The three main types of photochemical reactions which flavins take part in are photoreduction, 
photodealkylation and photoaddition (82). Some or all of these photoreactions may occur 
concurrently, depending upon the structure of the flavin and the reaction conditions.  
Photoreduction may occur as an intermolecular or intramolecular reaction. The overall 
reaction of the intermolecular reduction can be presented as follows (83):  
Fl* + RH ĺ H2Fl + R-products 
or 
HFlR 
(2)
Where Fl* is flavin in excited state, RH is a reducing agent, H2Fl is unsubstituted reduced 
form (1,5-dihydroflavin) and HFlR is a covalent adduct. Most reduced forms of flavins are 
oxidized by molecular oxygen. The unsubstituted reduced form reacts rapidly with 
consequent formation of hydrogen peroxide (83):  
H2Fl + O2ĺ H2O2 + Fl (3)
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The mechanism of the reduction is quite complex and involves a two step reduction via a 
semiquinone free radical intermediate (HFl•) (82, 83). Some of the suggested mechanisms of 
reduction involve a dimeric triplet state, triplet-ground state reaction or triplet-triplet reaction: 
2Fl ' Fl2 → 3Fl2 → Fl•+ + Fl•- (4a) 
Where 3Fl2 is a dimeric triplet state of flavins, Fl•+ and Fl•- are flavin radical species. The 
reaction between the ground (Fl) and triplet states (3Fl) is known as Dye-Dye reaction (D-D 
reaction).  
3Fl + Fl → Fl•+ + Fl•- (4b) 
Semi-reduced flavin (flavosemiquinone radical) and fully reduced flavin (1,5-dihydroflavin or 
flavohydroquinone) can be formed starting from flavin radical species: 
Fl•- + H+ → HFl• (5a) 
2HFl• → H2Fl + Fl (5b) 
Hemmerich et al. (84) showed formation of flavosemiquinone radicals in solution in the 
absence of the electron donors (reducing agents).  
Intramolecular reduction involves dehydrogenation of the hydroxyalkyl side chain on the N-
10 position to yield a variety of ketonic and aldehydic products. Riboflavin intramolecular 
photoreduction results in a complex mixture of 2’ and 4’ keto-derivatives together with 
formylmerthyl flavin (83). It has been suggested that for efficient intramolecular hydrogen-
transfer to occur, the side chain should be co-planar with the main flavin ring-system (82). 
Photodealkylation, a strictly intramolecular process, results in the formation of an alloxazine 
and an alkene. Photoaddition can occur as an intermolecular or intramolecular reaction 
(addition of cyanide, ammonia or water to benzenoid subnucleus of flavin, or addition of the 
C-2’ hydroxyl group at the C-9 position, respectively) (82, 83).   
3.3.2 Curcumin as the model of a photosensitizer for aPDT 
Curcumin, a yellow pigment, is a constituent of turmeric or the rhizome of the plant Curcuma 
longa L. Turmeric has been used in the traditional Chinese and Indian medicine for thousands 
of years (85). Curcumin is an established photosensitizer in aPDT (45, 86-91). Commercially 
available pure curcumin is a mixture of curcumin, demetoxycurcumin and 
bisdemetoxycurcumin, in which curcumin represents the main constituent (~77%) (92). 
27 
 
Curcumin synthetized according to Pabon (93) was used in the present work in order to avoid 
interference from the two other curcuminoids present in the commercially available product.  
Physico-chemical properties of curcumin 
Curcumin (diferuloylmethane) is composed of two phenyl rings bearing the methoxy group in 
meta- and OH group in para- positions, symmetrically linked through the β-diketone moiety. 
It exists as an equilibrium mixture of tautomers (Fig. 5). The compound is considered as a 
small lipophilic molecule (Mw = 368.38, log P = 2.5) (85). It is practically insoluble in water 
at acidic or neutral pH values (~3×10-8 M at pH < 7), but soluble in alkali. However it suffers 
from rapid hydrolytic degradation at pH > 7 (94, 95).  
 
Figure 5. The two tautomeric forms of curcumin 
Each of the two phenolic protons and the enolic proton are ionisable, with pKa values varying 
in the range 7.7 -10.7 (depending on the experimental conditions). At physiological pH of 7.4 
75-90% of curcumin will be in the neutral state (85).  
Both keto and enol tautomeric form of curcumin can exist in cis and trans conformation. In 
solution curcumin is predominantly present in the cis enol form which is characterized by 
strong intra-molecular hydrogen bond (H-bond) formation. Formation of the intramolecular 
H-bond leads to total π-system delocalization. In protic solvents inter-molecular H-bonds 
perturb the intra-molecular H-bond, while in polar aprotic solvents perturbation is likely to 
occur by a polarity effect (Fig. 6) (96).  
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Figure 6. Perturbation of intramolecular H-bond of curcumin in protic (upper reaction) and polar aprotic 
solvent (lower reaction). Adapted from (96). 
Curcumin absorbs strongly in the UV-Vis region of the electromagnetic spectrum with the 
absorption maximum (λAbs) between 408 and 434 nm, depending on the solvent. In aqueous 
based media λAbs ranges from 418 to 426 nm (85). The fluorescence spectrum, fluorescence 
maximum (λFl) and fluorescence quantum yield (ΦFl) have been found to be sensitive to the 
surrounding medium. The fluorescence spectral profiles are broad and structureless with the 
exception of spectra recorded in cyclohexane where three emission peaks occur. The central 
fluorescence peak in cyclohexane is at 470 nm. Redshift of λFl occurs in polar aprotic solvents 
(494-538 nm), and further redshift occurs in H-bond donating and accepting solvents (96). 
The fluorescence quantum yield (0.17 ≤ ΦFl ≤ 0.154) is found to be lowest in protic media and 
highest in non-polar media. The non-radiative processes dominate the radiative processes; the 
major relaxation pathway from the S1 is the excited state intramolecular proton transfer 
(ESIPT) which is facilitated by the tight intramolecular hydrogen bond.  
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Curcumin degrades upon exposure to UV-Vis radiation, both in solution and the solid state. 
Several degradation products are formed including vanillin, vanillic acid, ferulic aldehyde, 
ferulic acid, and 4-vinylguaiacol (97). Reported photodegradation quantum yields in methanol 
and acetonitrile are 0.021 and 0.06, respectively (96). The rate of photodegradation depends 
on the surrounding medium (98-100). Absorption and fluorescence maxima and fluorescence 
quantum yield of curcumin are affected by the binding to plasma proteins (human and bovine 
serum albumin) (85).   
Curcumin as a photosensitizer with antimicrobial effect 
The potential of curcumin as an antimicrobial and anticancer PS has been extensively studied 
over the past 25 years (8, 86, 88, 89, 101-104). The phototoxicity of curcumin is found to be 
oxygen dependent (101). The phototoxic effect is attributed to the production of ROS such as 
singlet oxygen (1O2) and superoxide anion (O2
•-). However, production of 1O2 was barely 
detectable in protic solvents (96, 105) and could not be detected the biological model 
involving Gram-negative (G-) bacteria (106). The role of singlet oxygen in curcumin 
phototoxicity is therefore not yet clear. The superoxide anion was detected upon irradiation of 
curcumin under both protic and non-protic conditions and may be involved in the 
photodynamic action of the compound (105). Studies on the uptake of curcumin by bacteria 
showed that the compound is adhered to G- bacteria Escherichia coli (E. coli). In Gram-
positive (G+) bacteria Enterococcus faecalis (E. faecalis) curcumin is either absorbed or 
adsorbed to the bacterial wall (8, 106). A recent study showed that photoactivated curcumin 
induced damage of the membrane integrity of  the G+ Staphylococcus aureus (S. aureus), 
leading to bacterial death (107).  
Low concentrations of curcumin are sufficient to photoinactivate a broad range of pathogenic 
species in vitro: G+ bacteria (8, 45, 107) including methicillin resistant S. aureus (88), G- 
bacteria (45, 91) and fungi (87, 89). Microbial cells were found more susceptible to the 
phototoxic effect of curcumin than the host cells (88, 89, 108) although significant reduction 
of the host cells was reported (88, 89). In a recent investigation of oral candidiasis caused by 
Candida albicans (C. albicans) in a murine model, curcumin mediated aPDT caused 
significant reduction in C. albicans viability without harming the host tissue of mice. Finally, 
studies on healthy humans showed that curcumin combined with blue light efficiently reduced 
the concentration of salivary microorganisms up to 2 h post-treatment (109, 110). No major 
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adverse effects were reported (110). The main properties of curcumin are compared to the 
properties of an optimal photosensitizer in Table 2. 
Table 2. Summary of the main properties of curcumin, compared to the properties of an optimal 
antimicrobial PS as described by Jori et al. (21).  
Optimal PS Curcumin 
Suitable photophysical characteristics: high 
extinction coefficient in the deeply tissue-
penetrating wavelength regions (mainly the 
red and far-red spectral interval); for 
treatment of superficial infections also the 
intensely absorbed blue light (400–420 nm) 
can be useful. A long-lived electronically 
excited triplet state, a high quantum yield for 
the generation of reactive oxygen species 
(i.e., singlet oxygen) when exposed to 
excitation with visible light. 
Absorbs strongly in the blue region and is, 
thus, suitable for superficial infections or pre-
surgical disinfection. The role of singlet 
oxygen in the microbial phototoxicity is not 
yet clear, the compound is considered to take 
part in both type I and type II reactions upon 
irradiation. 
A large affinity for the broadest possible 
classes of microbial cells. 
Affinity for several classes of microbial cells 
has been demonstrated. 
Preferential binding of the photosensitizer to 
the cytoplasmic membrane whose 
photosensitive constituents (e.g., unsaturated 
lipids, proteins) will consequently represent 
the main targets of the photoinactivation 
process; as a consequence cell death will 
mainly be caused by membrane damage 
rather than attack on the genetic material. 
The cytoplasmic membrane is hypothesized 
to be the main target of curcumin mediated 
aPDT. 
A broad spectrum of action on bacteria, 
fungi, yeasts and parasitic protozoa in order 
to achieve a high therapeutic effect also in the 
treatment of infections which are 
characterized by the presence of a 
heterogeneous flora of pathogens. 
Action on bacteria (including G+ and G-), 
fungi and yeasts has been demonstrated. 
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The research on curcumin as an antimicrobial PS is currently moving from in vitro to in vivo 
studies. Although application of curcumin in aPDT is limited by low penetration depth of blue 
light in tissue (111), the broad antimicrobial spectrum and efficacy of the compound (as 
shown in vitro) and few side effects (reported in the limited number of in vivo studies) make it 
an attractive candidate for treatment of, e.g., superficial wounds and oral infections that are 
characterized by the presence of a heterogeneous flora of pathogens (21). Additional 
advantages of curcumin are: cheap and easy production and purification (93), good 
tolerability when administrated orally (85) and fast elimination in vivo after oral 
administration (112).  
Formulation of curcumin as solid dispersion for ex tempore preparation of supersaturated 
solutions  
Within this work the possibility of formulating curcumin as a solid dispersion for ex tempore 
preparation of phototoxic supersaturated solutions has been explored. The high bacterial 
phototoxicity of curcumin in the supersaturated state has already been shown in vitro (45, 86-
91). However, to be beneficial clinically curcumin needs to be in a preparation which is 
convenient for storage and application. Therefore, readily dispersible SDs of curcumin able to 
generate curcumin supersaturated solutions of desired and reproducible concentration were 
developed. Precipitation inhibitors were included in the preparations in order to prolong the 
supersaturated state. The overall stability of ex tempore prepared supersaturated solutions (i.e., 
rate of precipitation and hydrolytic and photolytic stability of curcumin in the solutions) was 
estimated. Finally, phototoxicity against G+ and G- bacteria was tested (Papers II and III). 
Solid dispersion is a beneficial formulation approach for increasing apparent solubility and 
dissolution properties of curcumin. The high melting point of curcumin (183°C) reflects 
strong crystal lattice energy and therefore a major improvement in apparent solubility can be 
expected upon disruption of the crystalline structure (113). Indeed, the amorphous form of 
curcumin possesses higher solubility compared to its crystalline counterpart (114). The 
carriers selected for the SDs prepared within this work were aimed to meet two requirements: 
x to facilitate creation of supersaturated solutions quickly and easily upon dissolution of 
SDs 
x to enable a prolonged metastable  supersaturated state. 
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CDs and polymeric surfactants Pluronics® were selected for this purpose.  
The common criticism towards ex tempore preparation of solutions aimed for aPDT is that the 
procedure is not practical in a clinical setting when many people may need immediate 
treatment. Ex tempore preparation can also introduce error in dose if performed incorrectly 
(20). Suitable dosage forms consisting of premeasured SD of the compound with or without 
the adequate amount of the dissolution medium may facilitate the use and secure a correct 
dose. Another disadvantage of solution-based topical preparations is that they are hard to keep 
at the site of action (20). This may be resolved by addition of a viscosity modifier or 
mucoadhesive agent either to the dissolution medium or to the SD.  
The application of a solid preparation, on the other hand, does not require any manipulation 
before application and would be easier to keep at the target site. A disadvantage of such a 
system in this context is the dependence upon some liquid already present at the target site to 
facilitate dissolution. A solid preparation could also prevent the radiation from reaching the 
target and might need to be removed prior to irradiation.  
The general advantage of solid forms over creams, gels and solutions typically used in aPDT 
is increased stability and thus longer shelf-life of the product. However, in the case of solid 
dispersions an additional concern is the physical stability of the active ingredients within the 
matrix. Due to the possibility of a crystallization of active ingredients resulting in markedly 
changed bioavailability, the number of SD based products on the market is still very limited 
(60). The prototypes of solid dispersions for the preparation of supersaturated solutions as 
presented here, could be further modified according to the particular site of action and type of 
infection. 
33 
 
4. General experimental conditions 
A general description of materials, sample preparation and methods are given below. The 
specific experimental conditions are described in the individual papers (I-IV). 
4.1 Materials 
Riboflavin (both biosynthetic and synthetic sample) were generously provided as a gift by 
Weifa A/S (Oslo, Norway). Riboflavin dehydrate was produced by exposing a biosynthetic 
riboflavin sample to elevated humidity (Paper I). Curcumin was synthetized according to 
method described by Pabon (93).  
Hydroxypropyl-β-cyclodextrin (HP-β-CD) and HPMC were used for making SDs in Paper II. 
In Paper III Pluronics® F127, F68 and P123 (PF127, PF68 and PP123) were employed for 
production of SDs; HPMC, polyethylene glycol 400 (PEG 400) and hyaluronic acid (HA) 
were tested as the second PI. Within the Paper IV the effect of the following excipients on the 
photostability and the protein binding of curcumin was studied: hydroxypropyl-J-cyclodextrin  
(HP-J-CD), HP-β-CD, PEG 400 and PF127.  
4.2 Preparation of samples 
Within Paper II the solid dispersions were prepared in two steps. In the first step, co-
precipitates of curcumin and HP-β-CD were prepared by evaporation from methanol solutions 
with varying CD/curcumin molar ratios (0.5, 0.9, 1.8 and 2.8). Depending on the molar ratio, 
co-precipitates are referred to as 0.5, 0.9, 1.8 and 2.8. In the second step supersaturated 
curcumin solutions obtained by dissolving selected co-precipitates were added HPMC and 
freeze dried to yield the final product. Depending on the co-precipitate used for the production, 
lyophilizates are referred to as 0.9, 1.8 and 2.8. 
The solid dispersions made within Paper III were produced by the solvent evaporation method 
from methanol or methanol-dichloromethane solutions. The second PI was added to the 
dissolution medium to evaluate its potential to stabilize the supersaturated solution. 
Curcumin was added from a stock solution in methanol to the solutions containing the 
excipient of interest and/or human serum albumin within the Paper IV.  
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4.3 Methods 
The following methods were applied to identify the crystalline form of riboflavin in Paper I: 
X-ray diffractometry (XRD), Fourier-Transform Infrared Spectroscopy (FT-IR) and scanning 
electron microscopy (SEM). The influence of the radiation exposure on the samples was 
studied by visible (Vis)-, near Infrared (NIR)-, FT-IR and fluorescence reflectance 
spectroscopy. Qualitative thin layer chromatography (TLC) and HPLC were employed for the 
detection of amino acids and the degradation products of riboflavin. 
The solid dispersions and the co-precipitates of curcumin in Paper II were studied by 
differential scanning calorimetry (DSC), Carl-Fisher titration and SEM, to evaluate 
crystallinity of curcumin within SDs, morphology and the moisture content of SDs, 
respectively. The drug load was determined by HPLC. Solutions of solid dispersions were 
characterized by UV–Vis spectrophotometry and HPLC to estimate their physical stability 
and the hydrolytic stability of curcumin, respectively. Solutions of the selected SDs were 
assessed for potential phototoxicity towards E. coli.  
The solid dispersions produced within Paper III were examined by XRD to determine the 
physical state of curcumin. The dissolved SDs with and without the second PI added to 
dissolution medium, were studied by UV–Vis spectrophotometry to evaluate the stability of 
the supersaturated curcumin solutions. HPLC was employed to study hydrolytic and 
phototlytic stability of curcumin in the solutions. Supersaturated solutions of selected SDs 
were tested for phototoxic potential towards the bacterium E. faecalis. 
In Paper IV the effect of excipients on curcumin-HSA binding was studied using HSA 
fluorescence quenching. Absorption and fluorescence emission spectra of curcumin in the 
solutions containing HSA, excipients or both were recorded. HPLC was employed to study 
the effect of excipients and HSA on curcumin photostability.  
In Papers II, III and IV the samples were exposed to the radiation in the wavelength range 
350–500 nm (emission maximum at 430 nm) for the photostability studies and bacterial 
studies.  
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5. Results and discussion 
5.1 The physical state of the drug substance in the solid preparation 
The physical state of the drug substance can govern the physico-chemical properties of the 
substance and the final product such as melting point, solubility, stability, density and 
hardness (115). Some of these properties, such as solubility and stability, play a key role in 
the drug formulation and the quality of the final product. As part of this project, the influence 
of the physical state of PDS on the apparent solubility and dissolution rate, and photostability 
in the solid state was studied.  
5.1.1 The physical state of the riboflavin as a bulk substance applied in tablets 
A change in the production method of the active ingredient induced a change in the 
photostability of riboflavin tablets (section 3.3.1). The two different qualities of riboflavin 
were examined by means of XRD and FT-IR. Both techniques indicated a difference in the 
crystalline structure (Paper I). Synthetic riboflavin (RFs) and biosynthetic riboflavin (RFbs) 
were identified as the previously described forms anhydrate I and monohydrate II respectively, 
by means of XRD analyses (116). Furthermore, the previously described dihydrate II was 
prepared by exposing RFbs to elevated humidity and identified by XRD. The FT-IR study 
indicated the presence of a markedly different H-bonding pattern in the two forms of 
riboflavin. The morphology of RFs and RFbs crystals observed by SEM and the color of the 
powder correlated to previously reported morphology and color of anhydrate I and 
monohydrate II crystals, respectively (117). A clear difference in the shape of the 
fluorescence emission spectra of RFs and RFbs (in the solid state) could be observed. This 
was ascribed to the structural differences between the two examined forms of riboflavin.  
5.1.2 Formulation of curcumin as a solid dispersion  
In vitro studies showed that curcumin can be efficient in photoinactivation of G+ bacteria (E. 
faecalis) at concentrations as low as 5×10-7 M (combined with a radiation dose of 11 J/cm2) 
and of G– bacteria (E. coli) at concentrations of 5×10-6 and 10-5 M (combined with a radiation 
dose of 32 J/cm2 and 16 J/cm2, respectively) in an appropriate preparation (45). In a recent 
animal study in a murine model of oral candidiasis the most promising results of 
photoinactivation of C. albicans were achieved with the combination of a 8×10-5 M curcumin 
solution and a 37.5 J/cm2 radiation dose (90). A concentration of curcumin much higher than 
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the saturation solubility is required for the successful application of the compound as PS in 
aPDT in vivo. In Papers II and III the possibility of increasing the apparent solubility and 
dissolution rate by formulating curcumin as a solid dispersion was explored.  
Formulation of solid dispersions of curcumin in HP-β-CD and HPMC was a two step process 
(Paper II, section 4.2). In the first step the co-precipitates of curcumin and HP-β-CD were 
prepared and investigated by DSC. A loss of curcumin crystallinity was indicated in all of the 
samples except for the co-precipitate with CD/curcumin ratio of 0.5. This product was not 
studied further. Two glass transition temperatures (Tg) were observed for the remaining co-
precipitates. Neither could be superimposed on Tgs of the pure HP-β-CD or amorphous 
curcumin, suggesting the occurrence of inter-molecular interactions between the ingredients. 
The dissolution of the co-precipitates in water resulted in a supersaturated curcumin solution, 
as shown by the decrease in curcumin concentration upon prolonged dissolution. The 
concentration of dissolved curcumin depended on the CD/curcumin molar ratio of the co-
precipitates (Paper II). CD-curcumin interactions may dictate the physical state of the SD and 
thus affect the release of the active ingredient. Once the supersaturated solution is formed, a 
high concentration of HP-β-CD present in solutions of co-precipitates with a high 
CD/curcumin ratio may offer more efficient crystallization inhibition than corresponding 
solutions with a low CD/curcumin ratio (58).  
In the second production step lyophilizates 1.8 and 2.8 were selected for further studies based 
on the DSC investigations. These samples displayed uniform thermal behavior and batch to 
batch reproducibility. No crystalline curcumin was present in the freeze dried product, as 
indicated by the absence of the curcumin melting endotherm. Similar to co-precipitates, two 
Tgs were observed. This may indicate a mixed system comprised of the amorphous drug 
substance and the solid solution (118). However, the lyophilizates did not display the Tg of 
the amorphous curcumin. Therefore, two glass transitions may indicate the existence of two 
types of molecular interactions between curcumin and the carriers within the solid dispersions. 
Scanning electron microscopy of the lyophilizate 2.8 revealed the porous structure 
characteristic for freeze dried products.  
Dispersion of curcumin within the polymeric carriers was made by evaporation method and 
investigated for the presence of crystalline curcumin by XRD (Paper III). PF127 and PP123 
were combined with Pluronic®/curcumin in 0.5:1 and 1:1 molar ratio, while PF68 and 
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curcumin were combined in 1:1 and 2:1 molar ratio.  SDs based on PP123 could not be 
studied by XRD for practical reasons. The remaining four SDs showed no presence of 
crystalline curcumin. 
Solid dispersions presented here were made by use of the solvent method which has many 
advantages over the melting method but is associated with many ecological and economic 
problems. Because of this the current method of choice for the manufacturing of solid 
dispersions is hot melt extrusion (HME) (60). The low melting point of Pluronics® makes 
them suitable carriers for SD production by HME, since the technique requires one or more 
‘meltable’ excipients to be included in the carrier system (119, 120). Therefore HME should 
be considered for scaling up the production of Pluronic® based SDs.  
A combination of HP-β-CD and HPMC offered efficient crystallization inhibition of 
curcumin during freeze drying and amorphous final products were obtained (Paper II). The 
drug load of the final products was ranging from 0.5 to 1% w/w. In Paper III we show that no 
crystalline curcumin precipitated during fast evaporation of the common solvent at the given 
carrier/curcumin ratios, yielding solid dispersions with a drug load in the range 2.1 - 5.5% 
w/w. Within the same work the crystallinity of curcumin in the solid dispersions with the 
highest drug loads (i.e., 6.1 and 11.4% w/w, based on PP123) could not be determined by 
XRD for practical reasons. However, good dissolution properties and stability of the 
supersaturated solution formed upon dissolution of these SDs suggested the absence of a 
crystalline compound, as will be discussed later. Thus, the selected formulation methods 
combined with the selected carriers in the chosen ratios resulted in SDs with curcumin either 
transformed to an amorphous form or dispersed on a molecular level (i.e., as a solid solution). 
The physical state of the SDs depends on the physico-chemical properties of the carrier and 
active ingredient, active ingredient-carrier interactions and the formulation method. When 
prepared by the solvent method the physical state of SD depends on the temperature, the 
evaporation rate and the type of solvent (58). Curcumin can be considered an intermediate 
crystallizer according to the classification system of Van Eerdenbrugh et al. (113, 121). 
Therefore, it was not possible to obtain the amorphous curcumin by evaporation (Paper II), 
and curcumin-Pluronic® interactions were essential for the transformation of the physical state 
of the compound (Paper III). Wegiel et al. (113) have recently studied the physical stability of 
amorphous curcumin SDs and concluded that, for a compound like curcumin which forms 
intramolecular H-bonds, formation of H-bonding with the carrier is hindered and thus it is 
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more difficult to inhibit crystallization. The carrier of choice for the curcumin SDs should 
allow the formation of interactions other than H-bonds (113). Even though both cyclodextrins 
and Pluronics® may form H-bonds with curcumin the main types of interactions are inclusion 
complex formation (CDs) and hydrophobic interactions (Pluronics®) (98, 122). Thus, 
regarding the production and stability of SDs, as well as inhibition of the formed 
supersaturated solution upon dissolution, these carriers are good candidates for solid 
dispersions of curcumin.  
Table 3. Main properties of the selected curcumin solid dispersions. Lyophilizate number indicates 
CD/curcumin molar ratio of co-precipitate used for the production. SD - solid dispersion . Confer Paper III 
for further details on SD1, SD5 and SD7. 
Solid dispersion 
Property lyophilizate 1.8 
lyophilizate 
2.8 SD1 SD5 SD7 
Excipients HP-β-CD and HPMC 
HP-β-CD 
and HPMC 
Pluronic® 
F127 
Pluronic® 
P123 
Pluronic® F68 and 
HPMC 
Drug load (% w/w) 0.8 1 5.5 11.4 3.8 ƾ 
Production method 
Freeze drying of 
supersaturated aqueous 
solution 
Fast evaporation of 
methanol solution 
Fast evaporation of 
methanol-
dicholoromethane 
solution 
Dissolution properties Excellent Very good Good Very good 
Hydrated solid dispersion (10-5 M curcumin solution) 
Precipitation/degradation 
after 24h 18.7% * 18% * 10.1% * 7.53% * 22.4% ** 
Hydrolytic stability Optimal Suboptimal 
ƾTheoretical drug load, not confirmed by HPLC. (Paper III) 
* Decrease in curcumin concentration in the solution mainly ascribed to precipitation and/or agglomeration. 
** Decrease in curcumin concentration in the solution ascribed to a combination of 
precipitation/agglomeration and hydrolytic degradation. 
Dissolution of the curcumin solid dispersions 
Lyophilizates 1.8 and 2.8 containing HP-β-CD and HPMC (Paper II) could be hydrated within 
5 and 3 s, respectively, to yield ~10-5 M curcumin solutions. Some flaky particles did however, 
remain at the surface of the solutions after the hydration of lyophilizates. They disappeared 
within a few seconds when the solutions were gently stirred. The presence of two types of 
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curcumin-carrier interactions within the SDs as suggested by the presence of two Tgs may 
explain this behavior.  
Dissolution of SDs containing PF127 and PF123 based SDs resulted in 10-5 M curcumin 
solutions corresponding to the theoretical amount of the substance in the dissolved state. PF68 
based SDs were as easily dissolved but did not yield in the theoretical curcumin concentration 
(Table 3). 
The good dissolution properties of these SDs could be explained by good dissolution 
properties of the carriers, particle size reduction, change in the physical state of active 
ingredient and possibly dispersion at the molecular level (58). When the drug substance is 
dispersed at molecular level, the dissolution rate is determined by the dissolution rate of the 
carrier (60). Freeze dried SDs additionally benefit from their porous structure and the 
amorphous state of the carriers (i.e., HP-β-CD and HPMC) and display better dissolution 
properties than Pluronic® based SDs.  
A short incubation time prior to irradiation is favored in aPDT. Thus preparations with a fast 
drug release are required. The lyophilizates hydrated almost instantaneously, resulting in a 
clear solution. They were proposed for application on infected, moist wounds (Paper II). SDs 
based on Pluronics® are suggested to be used after hydration in the form of a supersaturated 
solution (Paper III). Pluronics® display a complex phase behavior. Depending on the 
temperature, polymer concentration and the type of polymer (polyethylene 
oxide/polypropylene oxide composition ratio), unimer, micellar, cubic (gel), hexagonal and 
lamellar phases can be observed (123). The drug release from each of these states differs. 
Depending upon viscosity of the preparation the light scattering/absorption could pose the 
problem if the preparation is not removed prior to exposure to radiation. Neither the amount 
of dissolution media (wound liquid/saliva) nor the temperature of the infected area can be 
controlled. Supersaturated solutions containing polymer in a submicellar concentration and 
prepared immediately before use, should be applied to control the release of curcumin from 
Pluronics® containing preparations.  
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5.2 Photoreactivity of the drug substance  
5.2.1 Photoreactivity of riboflavin in the solid state 
Photoinduced color change of riboflavin was observed for both qualities of the substance and 
the dihydrate produced for the purpose of the study in Paper I (Fig. 7). However, each 
riboflavin modification followed different patterns of the color change. RFbs showed the most 
pronounced initial color change but reversible after storage in the dark. RFs exhibited a less 
pronounced and irreversible color change. The color change of RFdh was the least 
pronounced but reversible. The surface color of RFdh continued to change throughout the 
measurements. This was ascribed to drying of the surface layers and transformation back to 
the riboflavin modification used for production of the dihydrate (monohydrate II). The color 
of the bulk material changed towards green upon exposure to light in all cases. No new 
products were detected by HPLC analyses of the light exposed samples (RFs and RFbs). It 
was therefore assumed that the change causing the discoloration was reversible by dissolution 
of the samples in water prior to the HPLC analyses. The green products could therefore only 
be observed in the solid state. It is also possible that the quantity of the new formed green 
product was below the detection limit of the HPLC method. The fluorescence intensity at the 
emission maximum decreased upon exposure to light for all the examined riboflavin samples 
(RFbs, RFs and RFdh). The fluorescence intensity of RFbs and RFdh was restored after 24 h 
storage in the dark (Paper I). 
41 
 
 
Figure 7. The total color change (ΔEa*b*) of synthetic riboflavin (RFs), biosynthetic riboflavin (RFbs) and 
riboflavin dihydrate II (RFdh) as a function of the lag-time between light exposure and detection of the 
surface color. The values for the dark controls are subtracted. 
Photoreduction of the riboflavin molecule may explain the color change towards green upon 
exposure to light. Recovery of original color in the case of RFbs and RFdh may be due to re-
oxidation in the presence of oxygen. The decrease in fluorescence signal indicates the 
reduction of riboflavin. The reduced riboflavin exhibits weak fluorescence compared to the 
strong fluorescence from the oxidized riboflavin (124). Furthermore, reduced forms of 
riboflavin (flavohydroquinone and flavosemiquinon) are both green and are prone to re-
oxidation in the presence of molecular oxygen (82, 125). The green crystals of reduced 
riboflavin produced by Ebitani et al., slowly oxidized to the yellow riboflavin when stored in 
air and could not be characterized by HPLC due to immediate conversion to the oxidized 
form upon dissolution (124).  
It was first suspected that an external electron donor, e.g., trace amounts of amino acids that 
may be present in the biosynthetic sample, could cause the photoreduction and extensive color 
change of RFbs.  However, no evidence supporting this claim was found (Paper I). 
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Photoreduction in the absence of an external electron donor could proceed via a dimeric 
triplet state, triplet-triplet or D-D reaction, in the presence of H+ (82, 83). Alternatively, 
intramolecular photoreduction may lead to reduction of the isoalloxazine nucleus and 
formation of ketonic and aldehydic functions in the ribityl side chain (see section 3.3.1). 
Although FT-IR and near infrared spectroscopy were employed to study the structural 
changes upon exposure to light, no conclusive results were obtained. Spectral changes 
potentially indicated irreversible intramolecular photoreducation of RFs although a strong 
evidence for the reduction of RFbs was not found. Our hypothesis on photoreduction was 
however, supported by the results obtained by Penzkofer (126). He studied the blue-light 
photoreduction of riboflavin and lumiflavin in solid starch (α-amylose) films and obtained 
results comparable to our findings. Photo-excitation of the flavin doped starch films caused 
repeatable, reversible reduction of flavins, as shown by the decrease in absorption, 
fluorescence and phosphorescence, which recovered in the dark. The authors suggested that 
starch acted as the reducing donor. The thereby generated oxystarch was the oxidizing agent 
of reduced flavins. Furthermore, hydrogen abstraction from the ribityl side chain is thought to 
contribute to the isoalloxazine nucleus reduction in the case of riboflavin in starch and the 
reason for the incomplete re-oxdation in the dark. 
The observed differences between RFs and RFbs in our study are most likely due to a 
difference in their crystalline structure. Some of the factors controlling solid state reactions 
are the separation distance, mutual orientation and the space symmetry of reactive functional 
groups. Furthermore, the conformation of the reacting molecule is dictated by the crystalline 
structure. In solid state reactions the intrinsic reactivity of a molecule is thought to be less 
important than the nature of the packaging of the neighboring molecules of the reactant (127).  
The course of the photoinduced reaction (e.g., D-D vs intramolecular reduction) can be 
governed by the mutual orientation of the molecules and inter- and intramolecular bonds in 
the crystal lattices of RFs and RFbs. A different availability of H+ required for formation of 
flavosemiquinone in a D-D or triplet-triplet reaction, can be expected in RFs (anhydrate) and 
RFbs (monohydrate). 
The crystal modification of riboflavin should be controlled either by controlling the 
production parameters or by recrystallization of the bulk material during the production of the 
bulk riboflavin material, in order to control photostability of the final product. Alternatively, 
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solid dispersions of riboflavin in an appropriate carrier can separate riboflavin molecules and 
prevent the inter- and intramolecular interactions that may lead to photoreaction. 
5.2.2 Photoreactivity of curcumin in solution 
The photostability of curcumin in Pluronic® (F127, P123 and F68) solutions obtained from 
dissolution of SDs was studied within Paper III. The curcumin photostability in Pluronic® 
(F127), CD (HP-J-CD) and PEG 400 solution of varying excipient concentration was 
examined in Paper IV.  
Curcumin (10-5 M) exhibited very low photostability in the presence of submicellar 
concentrations of PF127 or PP123 (5×10-6 M) whereas a slightly better photostability was 
observed in the presence of PF68 (10-5 M) and HPMC (0.001% w/v) (Paper III). A better 
photostability in the PF68 solution was correlated to a more rapid agglomeration of the 
compound observed in this solution compared to PF127 or PP123 solutions. 
Poor curcumin photostability was not limited to a low Pluronic® concentration. Curcumin 
solutions (5×10-6 M) containing 1.5×10-4, 2×10-3 or 4×10-3 M PF127 (i.e., above CMC) were 
also rapidly degraded upon exposure to radiation (Paper IV).  
HP-J-CD and PEG 400 offered increased protection against photodegradation. Solutions of 
curcumin (5×10-6 M) containing HP-J-CD or PEG 400 in the range 0.05 - 5% w/v exhibited 
comparable photostability, and considerably better than observed in Pluronic® solutions 
(Paper IV).  
Curcumin has previously been shown to be photochemically more stable in H-bonding media 
(e.g., alcohols, ethanol/buffer) than in polar non-H-bonding media (chloroform, acetonitrile, 
ethyl acetate) (94, 96, 97, 100). Solubilization of curcumin in micellar or CD solutions seems 
to have a destabilizing effect compared to that of the free molecule in alcohol or in 
alcohol/buffer solution (94, 100).  
Photochemical decomposition of curcumin competes with other deactivation routes for the 
loss of excitation energy, i.e., radiative and non-radiative photophysical processes (Fig. 2). 
The deactivation pathways intersystem crossing and photodecomposition are not dominant in 
polar solvents (H-bonding and non-H-bonding) in case of curcumin (96). The ESIPT is the 
leading non-radiative decay mechanism of S1 and it is faster when curcumin is in the 
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intramolecular H-bonded cis enol form. In H-bonding solvents formation of H-bonds between 
curcumin and solvent molecules results in the perturbation of intramolecular H-bonds and 
thereby prevents direct ESIPT (Fig. 6). The fast-decaying intramolecular H-bonded enol 
structure can be formed only after desolvation. However, alternative decay mechanism can be 
the delivery of excitation energy to the solvent molecules, which is expected to be highly 
enhanced when intermolecular H-bonds are formed. On the other hand, polar non-H-bonding 
solvents can also efficiently perturb intramolecular H-bonds and inhibit deactivation through 
ESIPT (Fig. 6), but their interactions with curcumin do not introduce new decay mechanisms. 
More pronounced photodecomposition of curcumin in polar non-H-bonding than in H-
bonding environments is probably the consequence of the less efficient non-radiative 
deactivation in the first case.  
Very low curcumin photostability in the Pluronic® solutions could be explained by analogy 
with polar non-H-bonding solvents. Ghosh et al. (129) suggested that the ESIPT mediated 
decay channel of curcumin is inhibited in Tween® 20, Tween® 80, Pluronics® P123 and F127 
micelles. Furthermore, the authors suggested that the decrease of ESIPT rate observed in 
polymeric micelles compared to micelles of conventional surfactants was a result of the 
interaction between curcumin and the lone pair oxygen of oxyethilene moiety (128, 129). 
Addition of cosolvents (PEG 400 or ethanol, 20% v/v) to micellar solutions of Pluronics® 
(P123, F127 or P85) was correlated to the transfer of curcumin from the core of the micelles 
to the bulk solvent and resulted in slightly increased photostability of curcumin, as reported 
by Singh et al. (98).  
Increased photostability of curcumin in HP-J-CD and PEG 400 solutions compared to 
Pluronic® solutions could be rationalized by a more efficient S1 deactivation pathway through 
energy transfer to solvent and/or solubilizer molecules. Fluorescence emission studies 
suggested that curcumin may be in a H-bonding environment in these media (Paper IV). 
However, other factors can influence the behavior of the excited state since the complexation 
with HP-J-CD may determine curcumin conformation and tautomeric form (130).  
Although CDs and PEG offer better photostabilization of curcumin compared to Pluronics®, 
other aspects of the formulation should also be considered such as phototoxicity of curcumin 
and inhibition of precipitation. Furthermore, the demands regarding the drug photostability 
depend upon the type of the preparation. Solid dispersions of curcumin as suggested to be 
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used in aPDT either in the solid state or after rehydration with an aqueous medium, could 
easily be protected from light exposure during the storage period, both before and after 
rehydration. Further, as a part of aPDT protocol, the application site could also be protected.  
5.3 Physical stability of the curcumin in solution  
Solid dispersions of curcumin were prepared within Papers II and III in order to increase the 
apparent solubility and dissolution rate of curcumin as discussed above. Solid dispersions 
typically yield supersaturated solutions of the active ingredient upon dissolution which are 
thermodynamically unstable systems prone to precipitation (55, 58). Following administration 
the drug substance must remain in solution to ensure a high and reproducible interaction with 
the target such as the bacterial membrane in the case of aPDT. Thus, precipitation of 
curcumin from hydrated SDs needs to be delayed for the relevant time period. 
5.3.1 Supersaturated solutions of curcumin prepared from the solid dispersions  
The decrease in curcumin concentration in the solutions of lyophilizates 1.8 and 2.8 
(theoretical curcumin concentration of 1×10-5 and 2.5×10-5 M) upon storage (up to 168 h) and 
the decrease in UV-Vis absorbance of the solutions during 24 h storage suggested the 
agglomeration and precipitation of the substance since no indications of hydrolytic 
degradation products were found by HPLC (Paper II). Furthermore, the shape of the 
absorption spectrum of curcumin in dissolved lyophilizate indicated the presence of the free 
curcumin molecule rather than the curcumin-HP-β-CD complex.  
A decrease in curcumin concentration and UV-Vis absorbance upon storage (2, 8 and 24 h) 
were also observed for dissolved Pluronic®-based SDs (Paper III). 
Thus, both the HP-β-CD-HPMC based SDs prepared within Paper II and Pluronic® based SDs 
prepared in Paper III can generate supersaturated solutions of curcumin. 
5.3.2 Precipitation inhibition of curcumin in a supersaturated solution  
Solutions of lyophilizates 1.8 and 2.8 equivalent to 10-5 M curcumin exhibited a decrease in 
curcumin concentration ≥ 18% within 24 h (Paper II). Solutions of PF127 and PP123 based 
SDs (10-5 M curcumin) showed a decrease in curcumin concentration ≥ 10% during the 24 h 
storage whereas solutions of PF68 based SDs exhibited much more pronounced curcumin 
precipitation, comparable to that of a supersaturated solution without PI. The capability of the 
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second PI (HPMC, PEG 400 and HA) to improve the physical stability of curcumin 
supersaturation obtained from Pluronic® based SDs was evaluated. HPMC showed the best 
results and SD based on PF68 was reformulated by addition of this excipient. However, this 
SD was shown to be hydrolytically unstable in solution and was therefore not studied further 
(Paper III). 
In general, PF127 and PP123 based SDs showed better physical stability in the solution than 
HP-β-CD-HPMC based SDs, despite a 5-10 times higher drug load in the former (Table 3). 
Thus, PF127 and PP123 can be considered better precipitation inhibitors for curcumin than 
the combination of HP-β-CD and HPMC. It is difficult however, to distinguish between the 
contribution of each of the excipients included in the lyophilizates to the stability of the 
supersaturated solutions generated from these lyophilizates.   
HP-β-CD and HPMC have been proposed to interact with an active ingredient by establishing 
H-bonds which increase the activation energy of the crystal nucleation. Furthermore, due to 
the ability to form H-bonds these excipients can adsorb to the crystal surface and prevent the 
crystal growth (57, 131, 132). Similarly, Pluronics® are suggested to adsorb to the crystal 
surface and inhibit crystal nucleation and growth (133-135). However, a hydrophobic reaction 
between Pluronics® and the active ingredient is expected to be the main driving force behind 
the precipitation inhibition mechanism (134). HP-β-CD and Pluronics® can improve the 
solvation of the drug substance in solution and thereby increase the activation energy for 
desolvation during the crystal growth (55, 133, 136). Finally, HP-β-CD and Pluronics® can 
solubilize the drug substance and decrease the degree of supersaturation (137, 138). Curcumin 
is however, not expected to be in the solubilized state in the examined SD solutions and the 
delay of precipitation is not likely due to solubilization. Dissolved lyophilizates probably 
contain curcumin in a free form rather than complexed with HP-β-CD, as indicated by the 
UV-Vis spectra. Pluronic® based SD solutions contain submicellar concentrations of 
Pluronics® and therefore curcumin is most likely in the molecular state rather than 
encapsulated in micelles.    
The mechanisms suggested to explain precipitation inhibition by HP-β-CD and HPMC on the 
one side and Pluronics® on the other, largely overlap. However, the main difference seems to 
be the type of interactions that these excipients form with the substance i.e., H-bonds (HP-β-
CD and HPMC) or hydrophobic interaction (Pluronics®). It has been suggested that the 
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excipients mainly forming H-bonds with curcumin are not optimal carriers to inhibit 
crystallization of amorphous curcumin in the solid dispersions due to the strong 
intramolecular H-bonds in curcumin (113). Curcumin forms intramolecular H-bonds in the 
solution as well as in the solid state. Therefore Pluronics® F127 and P123 may inhibit 
precipitation of dissolved curcumin more efficiently than the combination of HP-β-CD and 
HPMC because the former mainly form hydrophobic bonds with curcumin. PF127 and PP123 
were found to be more efficient in stabilizing supersaturation than PF68, likely due to the 
larger size of hydrophobic polypropylene oxide block of the two former copolymers (Paper 
III). This emphasizes the importance of the hydrophobic interactions between the excipients 
and curcumin for the physical stability of a supersaturated solution.  
The various supersaturated solutions formed from the SDs may not have the same individual 
requirements for the physical stability. SDs based on the Pluronics® need to be rehydrated 
prior to application (as discussed in the section 5.1.2) and thus the curcumin solutions need to 
be stable both during the short term storage and the in vivo incubation time. Application of the 
SDs based on combined HP-β-CD-HPMC in the solid state requires only the stabilization of 
the curcumin supersaturation during the in vivo incubation time.  
5.4 Preparations in biorelevant media: bacterial phototoxicity of curcumin 
and interaction with human serum albumin 
Sensitivity of bacteria to photodynamic inactivation by curcumin in vitro was shown to be 
dependent upon the formulation. A similar effect could be expected under physiological 
conditions (8, 45, 139). It is therefore essential to optimize the formulation in regard to 
interaction with bacterial cells prior to in vivo studies. Dai et al. (19) pointed out that for 
aPDT to be clinically useful a combination of PS and light needs to be able to kill microbial 
cells in the environment found in actual infections. A number of in vitro studies showed the 
reduction of the aPDT effect in protein rich media (e.g., serum, saliva, albumin suspensions). 
The decrease in PS molecules available for interaction with bacteria due to competitive 
binding to the proteins present in the media was suggested as one of the causes of the 
described effect (37). It is therefore important to investigate how the formulation will affect 
the protein-curcumin binding.  
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5.4.1 Phototoxicity of curcumin towards Gram-positive and Gram-negative bacteria 
Encouraging in vitro aPDT results and the recently reported in vivo study emphasize the 
potential of curcumin as a PS (88-90, 108). The required concentration of curcumin in these 
studies was achieved by use of DMSO (10%) or ethanol as a cosolvent. DMSO is 
immediately being absorbed through human tissues and it can carry dissolved substances with 
it across the membranes. This is undesirable in the case of aPDT where local action is the 
main aim. Furthermore, high concentration of DMSO can have a damaging effect on the 
tissue and use of this solvent as an enhancer produces a foul odour on the breath (140). 
Therefore alternative formulation approaches should be found for the application of curcumin 
in a clinical setting. A number of formulations with curcumin solubilized by use of 
cyclodextrins, micelles and polymers were developed to avoid use of DMSO or other organic 
solvents (8, 102, 141). A high concentration of curcumin was achieved by use of CDs or 
micelles but the PDT effect was decreased (even completely lost in the case of 5% HP-β-CD 
and J-CD) compared to formulations with organic cosolvents (5% DMSO or 1% ethanol) (8, 
102). This clearly showed that a high concentration of solubilized curcumin is not sufficient 
for the phototoxic effect. To be efficient curcumin needs to be in the free molecular form 
rather than complexed or encapsulated. Application of supersaturation rather than inclusion 
complexation enhances the free curcumin concentration and facilitates interaction with the 
microbial outer wall (55, 91).  
Supersaturated curcumin solutions cannot be stored for longer periods due to rapid 
precipitation. Even phototoxicity, shown to be high in vitro, might decrease in vivo if the 
longer incubation times are required (141). Solid dispersions made within Papers II and III 
were aimed to generate supersaturated solutions upon hydration without the use of organic 
cosolvents and to maintain physical stability of supersaturation and hydrolytic stability of 
curcumin for the sufficient time periods. Phototoxicity of selected hydrated solid dispersions 
was studied against G– bacteria E. coli (Paper II) and G+ bacteria E. faecalis (Paper III). A 
phototoxic effect higher than or comparable to the one previously obtained with a 5% DMSO 
preparation proved that the stabilizing effect by the excipients did not reduce the curcumin 
efficiency (Table 4).  
Further development of the supersaturation concept gave improved results. Wikene et al. (45) 
have described solid dispersions based on a M-β-CD-HPMC or M-β-CD-HPMC-HA 
49 
 
combination produced by lyphilization. Solutions of these SDs efficiently eradicated E. coli 
and E. faecalis at a concentrations 2.5×10-6 and 5×10-7 M respectively, and the results 
corresponded to a reference supersaturated curcumin solution containing 1% ethanol (45). 
Winter et al. described a PVP based solid formulation of curcumin and examined 
phototoxicity against S. aureus and E. coli upon dissolution in aqueous media (139). The 
minimal concentration required for successful inactivation of  S. aureus was 5×10-6 M 
(≥99.99% reduction of viable bacteria), and thus could be compared to the results previously 
obtained with a 10% DMSO curcumin solution as demonstrated by Ribeiro et al (88). 
However, this preparation was less efficient in photoinactivation of E. coli than 5% DMSO 
solutions reported by Haukvik et al. (8). The curcumin-PVP solution was unstable as shown 
by the authors, and the adequate concentration may not be maintained long enough for the 
preparation to interact with the bacteria. This may explain the lower activity of the PVP 
preparation towards E. coli than the reference DMSO containing solution.  
Work presented here shows that the supersaturation approach is a realistic alternative to the 
DMSO preparations typically applied in aPDT with curcumin.  
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Table 4. Phototoxic effect of curcumin preparations: comparison of hydrated solid dispersions (Papers II 
and III) and preparations with 5% DMSO (Haukvik et al.) (8) .  
Type of preparation 
Minimal curcumin concentration [M] and irradiation [J/cm2] 
required for photoinactivation of bacteria 
E. coli E. faecalis 
Curcumin 
concentration 
Irradiation 
Curcumin 
concentration 
Irradiation 
HP-β-CD-HPMC based SD 
(lyophilizate 2.8) * 2.5×10
-5 14 
  
Pluronic® F127 based SD 
(SD1) *   
10-6 9.4 
Pluronic® P123 based SD 
(SD5) *   
10-6 9.4 
5% DMSO ** 2.5×10-5 30 2.5×10-6 0.5 
* Complete bacterial inactivation, corresponding to a 6 log10 reduction of viable bacteria. 
** Less than 0.2% bacterial survival corresponding to a 3 log10 reduction of viable bacteria. 
5.4.2 Formulation dependent binding of curcumin to human serum albumin  
The protein content of saliva ranges from 0.1 to 0.3% while wound fluids which are mainly 
serum derived, contain between 0.15 (acute) and 0.06% (chronic wounds) proteins (142, 143). 
Binding of PS molecules to serum proteins is likely to impact the efficiency of aPDT 
treatment of oral infections or infected wounds. Curcumin has been shown to bind to human 
serum albumin (HSA) with moderate affinity (144-146). The potential of selected excipients 
to influence curcumin binding to HSA was examined within Paper IV. HSA-curcumin 
binding studies were carried out in 3×10-6 M HSA solution, corresponding to 0.02% w/v. It 
was found that HP-J-CD, HP-β-CD and Pluronic® F127 interfere with curcumin-protein 
binding. Inhibition of HSA fluorescence quenching by curcumin with an increase in excipient 
concentration was observed in the concentration range 0-0.5% w/v. Fluorescence quenching 
of HSA by curcumin was ascribed to the formation of a protein-ligand complex. Inhibition of 
the quenching may indicate a decrease in curcumin binding to HSA (147). It was assumed 
that protein and excipients (Ex) compete for curcumin (Cur) and with the increase in excipient 
concentration the equilibrium tends to be shifted from a HSA-curcumin (HSA-Cur) towards a 
curcumin-excipient (Cur-Ex) complex (Eq 6). At about 0.5% excipient concentration the 
majority of the curcumin molecules is already associated with the excipients and a further 
increase in excipient concentration did not largely affect the fluorescence quenching.   
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HSA-Cur + Ex ' HSA + Cur + Ex ' HSA + Cur-Ex (6) 
This model did not take into account the possible interaction between HSA and excipients. 
Relying on literature data and the results obtained within the present study it was assumed 
that excipient-protein interactions are not considerably influencing HSA-curcumin binding. 
However, it is reasonable to expect excipient-protein interactions, particularly at high 
excipient concentrations.   
The study of curcumin fluorescence spectra showed that an increase from low (0.05% CDs, 
0.19% PF127) to high (5% CDs, 5.04% PF127) excipient concentration at constant protein 
concentration resulted in evident change in the curcumin microenvironment. The change in 
excipient concentration indicated a shift from the complex with HSA towards the complex 
with the excipients and thus confirmed the findings of the fluorescence quenching study.  
PEG 400 also influenced the HSA fluorescence quenching by curcumin but in the different 
manner than PF127 and CDs. Constant inhibition of the HSA fluorescence quenching was 
observed over the whole investigated PEG 400 concentration range (0-5%). The study of 
curcumin fluorescence spectra showed that even at the highest examined PEG 400 
concentration curcumin was still associated with HSA. It has been suggested that the decrease 
in fluorescence quenching is caused by a PEG 400-HSA interaction.  
A considerable impact of proteins on curcumin aPDT effect might be expected if the excipient 
concentration at the application site is low (e.g., supersaturated solutions) or excipients have 
low affinity for PS. Formulations leading to high excipient concentration upon application 
(e.g., curcumin solubilized by complexation with CDs or micellar solutions) with high affinity 
for PS may be less affected by the presence of proteins.   
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6. Conclusion  
x Any modification of the production of bulk material or the final product that may 
introduce a change in the physical state of the PDS can alter the photostability of PDS 
and the final product in the solid state. Therefore, the physical state of the PDS should 
be assessed after a modification of the production method accompanied by a 
photostability study of the bulk material/final product according to the ICH Guidelines 
(6). The type and concentration of excipients can strongly influence the photostability 
of the PDS in solution. The overall effect is difficult to predict and each combination 
must be investigated separately.  
x A supersaturated solution increases the thermodynamic activity of the photosensitizer 
curcumin and enhances the delivery to the target bacterial cells thereby enhancing the 
efficiency of aPDT. Furtheremore, solid dispersions which can create the state of 
supersaturaton provide a fast delivery of the PS. This is one of the requirements for the 
drug delivery systems aimed for aPDT.  
x Supersaturated solutions need to be physically stabilized for the time period sufficient 
for both in vivo interaction and the short in vitro storage period. Although both the 
HP-β-CD-HPMC combination and Pluronics® F127 and P123 provided satisfactory 
physical and hydrolytic stability of curcumin in the solution, Pluronics® were shown 
to be better precipitation inhibitors, emphasizing the importance of hydrophobic 
interactions between curcumin and the PI. 
x The type and concentration of excipients affect curcumin binding to plasma protein 
(HSA). Cyclodextrins and PF-127 seem to compete with HSA for curcumin, whereas 
PEG 400 appears to affect binding differently. The complexation of curcumin with 
plasma proteins can in turn influence aPDT efficiency through e.g., changed uptake of 
PS by the target cells or modified photoreactivity of the PS. 
 
53 
 
References  
1. Aulton ME. Pharmaceutics: the science of the dosage form design. Second edition 
London, UK: Churchill Livingstone; 2002. 
2. Tønnesen HH. Introduction: photostability testing of drugs and drug formulations - 
why and how? In Tønnesen HH, editor. Photostability of drugs and drug formulations. Second 
edition Boca Raton, USA: CRC Press LLC; 2004. p. 1-9. 
3. Tønnesen HH. Formulation approaches for improving solubility and its impact on drug 
photostability. In Tønnesen HH, editor. Photostability of drugs and drug formulations. Second 
edition Boca Raton, USA: CRC Press LLC; 2004. p. 351-73. 
4. Aman W, Thoma K. The influence of formulation and manufacturing process on the 
photostability of tablets. Int J Pharm. 2002;243(1-2):33-41. 
5. Kristensen S. Photostability of parenteral products. In Tønnesen HH, editor. 
Photostability of drugs and drug formulations. Second edition Boca Raton, USA: CRC Press 
LLC; 2004. p. 303-31. 
6. ICH Q1B  Harmonised tripartite guideline on stability testing: photostability testing of 
new drug substances and products. Fed Reg. 1997; 62, 27115-22. 
7. Ahmad I, Vaid FHM. Photochemistry of flavins in aqueous and organic solvents. 
Compr Ser Photochem Photobiol Sci. 2006;6:13-40. 
8. Haukvik T, Bruzell E, Kristensen S, Tønnesen HH. Photokilling of bacteria by 
curcumin in different aqueous preparations. Studies on curcumin and curcuminoids XXXVII. 
Pharmazie. 2009;64(10):666-73. 
9. Allen JM, Allen SK. Basic principles of drug photostability testing. In Piechocki JT 
and Thoma K, editors. Pharmaceutical photostability and stabilization technology. New York, 
USA: Informa Healthcare; 2007. p. 79-87. 
10. Evans RC, Douglas P, Burrow HD, editors. Applied Photochemistry. New York, USA: 
Springer; 2013. 
54 
 
11. Moore DE. Photophysical and photochemical aspects of drug stability. In Tønnesen 
HH, editor. Photostability of drugs and drug formulations. Second edition Boca Raton, USA: 
CRC Press LLC; 2004. p. 9-41. 
12. Dolmans DEJGJ, Fukumura D, Jain RK. Timeline: Photodynamic therapy for cancer. 
Nat Rev Cancer. 2003;3(5):380-7. 
13. Garland MJ, Cassidy CM, Woolfson D, Donnelly RF. Designing photosensitizers for 
photodynamic therapy: strategies, challenges and promising developments. Future Med Chem. 
2009;1(4):667-91. 
14. Greenhill JV, McLelland MA. Photodecomposition of drugs. Prog Med Chem. 
1990;27:51-121. 
15. Glass BD, Novak C, Brown ME. The thermal and photostability of solid 
pharmaceuticals. J Therm Anal Calorim. 2004;77(3):1013-36. 
16. Moore DE. Standardization of kinetic studies of photodegradation reactions. In 
Tønnesen HH, editor. Photostability of drugs and drug formulations. Second edition Boca 
Raton, USA: CRC Press LLC; 2004. p. 41-67. 
17. Tønnesen HH, Kristensen S. In vitro screening of the photoreactivity of antimalarials: 
a test case. In Tønnesen HH, editor. Photostability of drugs and drug formulations. Second 
edition Boca Raton, USA: CRC Press LLC; 2004. p. 213-35. 
18. Craig RA, McCoy CP, Gorman SP, Jones DS. Photosensitisers - the progression from 
photodynamic therapy to anti-infective surfaces. Expert Opin Drug Delivery. 2015;12(1):85-
101. 
19. Dai T, Huang Y-Y, Hamblin MR. Photodynamic therapy for localized infections - 
state of the art Photodiagnosis Photodyn Ther. 2009;6(3-4):170-88. 
20. Cassidy CM, Tunney MM, McCarron PA, Donnelly RF. Drug delivery strategies for 
photodynamic antimicrobial chemotherapy: from benchtop to clinical practice. J Photochem 
Photobiol, B. 2009;95(2):71-80 
21. Jori G, Camerin M, Soncin M, Guidolin L, Coppellotti O. Antimicrobial 
photodynamic therapy: basic principles. In Hamblin MR, Jori G, editors. Photodynamic 
55 
 
inactivation of microbial pathogens: medical and environmental Applications. London, UK: 
RSC Publishing; 2011. p. 1-19. 
22. Jori G. Photodynamic therapy of microbial infections: state of the art and perspectives. 
J Environ Pathol Toxicol Oncol. 2006;25(1-2):505-19. 
23. Hegge AB. Formulation of a hydrophobic photosensitizer for topical photodynamic 
therapy. Oslo, Norway: University of Oslo; 2010. 
24. Winckler KD. Special section: Focus on anti-microbial photodynamic therapy (PDT). 
J Photochem Photobiol, B. 2007;86(1):43-4. 
25. Vallner JJ. Binding of drugs by albumin and plasma protein. J Pharm Sci. 
1977;66(4):447-65. 
26. Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum 
albumin: from bench to bedside. Mol Aspects Med. 2012;33(3):209-90. 
27. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part 
three - photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of 
tumor destruction. Photodiagn Photodyn Ther. 2005;2(2):91-106. 
28. Bose B, Dube A. Interaction of Chlorin p6 with bovine serum albumin and 
photodynamic oxidation of protein. J Photochem Photobiol, B. 2006;85(1):49-55. 
29. Pandey RK, Constantine S, Tsuchida T, Zheng G, Medforth CJ, Aoudia M, et al. 
Synthesis, photophysical properties, in vivo photosensitizing efficacy, and human serum 
albumin binding properties of some novel bacteriochlorins. J Med Chem. 1997;40(17):2770-9. 
30. Cunderlikova B, Sikurova L, Moan J. pH, serum proteins and ionic strength influence 
the uptake of merocyanine 540 by WiDr cells and its interaction with membrane structures. 
Bioelectrochemistry. 2003;59(1-2):1-10. 
31. Lang K, Mosinger J, Wagnerova DM. Photophysical properties of porphyrinoid 
sensitizers non-covalently bound to host molecules; models for photodynamic therapy. Coord 
Chem Rev. 2004;248(3-4):321-50. 
56 
 
32. Moan J, Juzenas P. Biological effects of combinations of drugs and light. In Tønnesen 
HH, editor. Photostability of drugs and drug formulations. Second edition Boca Raton, USA: 
CRC Press LLC; 2004. p. 189-213. 
33. Moan J, Rimington C, Malik Z. Photoinduced degradation and modification of 
Photofrin II in cells in vitro. Photochem Photobiol. 1988;47(3):363-7. 
34. Krieg M, Whitten DG. Self-sensitized photooxidation of protoporphyrin IX and 
related free-base porphyrins in natural and model membrane systems. Evidence for novel 
photooxidation pathways involving amino acids. J Am Chem Soc. 1984;106(8):2477-9. 
35. Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to 
infectious disease? Photochem Photobiol Sci. 2004;3(5):436-50. 
36. Nitzan Y, Balzam-Sudakevitz A, Ashkenazi H. Eradication of Acinetobacter 
baumannii by photosensitized agents in vitro. J Photochem Photobiol B. 1998;42(3):211-8. 
37. Komerik N, Wilson M. Factors influencing the susceptibility of Gram-negative 
bacteria to toluidine blue O-mediated lethal photosensitization. J Appl Microbiol. 
2002;92(4):618-23. 
38. Lambrechts SAG, Aalders MCG, Verbraak FD, Lagerberg JWM, Dankert JB, 
Schuitmaker JJ. Effect of albumin on the photodynamic inactivation of microorganisms by a 
cationic porphyrin. J Photochem Photobiol, B. 2005;79(1):51-7. 
39. Wilson M, Mia N. Effect of environmental factors on the lethal photosensitization of 
Candida albicans in vitro. Laser Med Sci. 1994;9(2):105-9. 
40. Chen J, Cesario TC, Rentzepis PM. Rationale and mechanism for the low 
photoinactivation rate of bacteria in plasma. Proc Natl Acad Sci U S A. 2014;111(1):33-8. 
41. Schiffner U, Cachovan G, Bastian J, Sculean A, Eick S. In vitro activity of 
photoactivated disinfection using a diode laser in infected root canals. Acta Odontol Scand. 
2014;72(8):673-80. 
42. Tønnesen HH. Formulation and stability testing of photolabile drugs. Int J Pharm. 
2001;225(1-2):1-14. 
57 
 
43. Nyqvist H, Wadsten T. Preformulation of solid dosage forms: light stability testing of 
polymorphs as a part of a preformulation program. Acta Pharm Technol. 1986;32(3):130-2. 
44. Chongprasert S, Griesser UJ, Bottorff AT, Williams NA, Byrn SR, Nail SL. Effects of 
freeze-dry processing conditions on the crystallization of pentamidine isethionate. J Pharm 
Sci. 1998;87(9):1155-60. 
45. Wikene KO, Hegge AB, Bruzell E, Tønnesen HH. Formulation and characterization of 
lyophilized curcumin solid dispersions for antimicrobial photodynamic therapy (aPDT): 
studies on curcumin and curcuminoids LII. Drug Dev Ind Pharm. 2014:1-9. 
46. Bouma M, Nuijen B, Sava G, Perbellini A, Flaibani A, van Steenbergen MJ, et al. 
Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic 
ruthenium complex NAMI-A. Int J Pharm. 2002;248(1-2):247-59. 
47. Loftsson T, Jarho P, Masson M, Jaervinen T. Cyclodextrins in drug delivery. Expert 
Opin Drug Delivery. 2005;2(2):335-51. 
48. Asker AF, Habib MJ. Effect of certain stabilizers on photobleaching of riboflavin 
solutions. Drug Dev Ind Pharm. 1990;16(1):149-56. 
49. Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers 
for photodynamic therapy. J Photochem Photobiol, B. 2002;66(2):89-106. 
50. Donnelly RF, Cassidy CM, Tunney MM. Photosensitizer delivery for photodynamic 
antimicrobial chemotherapy. In Hamblin MR, Jori G, editors. Photodynamic inactivation of 
microbial pathogens: medical and environmental applications. London, UK: RSC Publishing; 
201. P. 187-216. 
51. Jori G, Fabris C, Soncin M, Ferro S, Coppellotti O, Dei D, et al. Photodynamic 
therapy in the treatment of microbial infections: basic principles and perspective applications. 
Lasers Surg Med. 2006;38(5):468-81. 
52. Jori G, Coppellotti O. Inactivation of pathogenic microorganisms by photodynamic 
techniques: mechanistic aspects and perspective applications. Anti-Infect Agents Med Chem. 
2007;6(2):119-31. 
58 
 
53. Felton LA. Physicochemical principles of pharmacy, 4th Edition, Florence AT and 
Attwood D. Drug Dev Ind Pharm. 2007;33(2):209. 
54. Higuchi T. Physical chemical analysis of percutaneous absorption process from 
creams and ointments. J Soc Cosmet Chem. 1960;11:85-97. 
55. Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the 
answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549-72. 
56. Rodriguez-Hornedo N, Murphy D. Significance of controlling crystallization 
mechanisms and kinetics in pharmaceutical systems. J Pharm Sci. 1999;88(7):651-60. 
57. Brewster ME, Vandecruys R, Peeters J, Neeskens P, Verreck G, Loftsson T. 
Comparative interaction of 2-hydroxypropyl-β-cyclodextrin and sulfobutylether-β-
cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated 
drug solutions. Eur J Pharm Sci. 2008;34(2-3):94-103. 
58. Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. J 
Pharm Pharmacol. 2009;61(12):1571-86. 
59. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral 
bioavailability of poor water soluble drugs. Drug Discovery Today. 2007;12(23&24):1068-75. 
60. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid 
dispersions. Eur J Pharm Biopharm. 2000;50(1):47-60. 
61. Choudhary S, Kishore N. Drug-protein interactions in micellar media: thermodynamic 
aspects. J Colloid Interface Sci. 2014;413:118-26. 
62. Lu J, Owen SC, Shoichet MS. Stability of self-assembled polymeric micelles in serum. 
Macromolecules (Washington, DC, U S). 2011;44(15):6002-8. 
63. Buggins TR, Dickinson PA, Taylor G. The effects of pharmaceutical excipients on 
drug disposition. Adv Drug Delivery Rev. 2007;59(15):1482-503. 
64. Egan TD, Kern SE, Johnson KB, Pace NL. The pharmacokinetics and 
pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus 
propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic 
study in a porcine model. Anesth Analg. 2003;97(1):72-9. 
59 
 
65. Piel G, Evrard B, Van Hees T, Delattre L. Comparison of the i.v. pharmacokinetics in 
sheep of miconazole-cyclodextrin solutions and a micellar solution. Int J Pharm. 
1999;180(1):41-5. 
66. Kurkov SV, Loftsson T, Messner M, Madden D. Parenteral delivery of HPβCD: 
effects on drug-HSA binding. AAPS Pharm Sci Tech. 2010;11(3):1152-8. 
67. Uekama K. Cyclodextrins in drug delivery systems. Adv Drug Delivery Rev. 
1999;36(1):1-2. 
68. Monti S, Sortino S. Photoprocesses of photosensitizing drugs within cyclodextrin 
cavities. Chem Soc Rev. 2002;31(6):371. 
69. Partyka M, Au BH, Evans CH. Cyclodextrins as phototoxicity inhibitors in drug 
formulations: studies on model systems involving naproxen and β-cyclodextrin. J Photochem 
Photobiol, A. 2001;140(1):67-74. 
70. Massey V. The chemical and biological versatility of riboflavin. Biochem Soc Trans. 
2000;28(4):283-96. 
71. Goldsmith G. Riboflavin Deficiency. In Rivlin R, editor. Riboflavin. New York, US: 
Springer; 1975. P. 221-302. 
72. Powers HJ. Riboflavin (vitamin B-2) and health. Am J Clin Nutr. 2003;77(6):1352-60. 
73. DeRitter E. Vitamins in pharmaceutical formulations. J Pharm Sci. 1982;71(10):1073-
96. 
74. Allwood MC, Kearney MCJ. Compatibility and stability of additives in parenteral 
nutrition admixtures. Nutrition. 1998;14(9):697-706. 
75. Chen MF, Boyce HWJr, Triplett L. Stability of the B vitamins in mixed parenteral 
nutrition solution. JPEN, J Parenter Enteral Nutr. 1983;7(5):462-4. 
76. Smith JL, Canham JE, Wells PA. Effect of phototherapy light, sodium bisulfite, and 
pH on vitamin stability in total parenteral nutrition admixtures. JPEN, J Parenter Enteral Nutr. 
1988;12(4):394-402. 
60 
 
77. Min DB, Boff JM. Chemistry and reaction of singlet oxygen in foods. Compr Rev 
Food Sci Food Saf. 2002;1(1):58-72. 
78. Habib MJ, Asker AF. Photostabilization of riboflavin by incorporation into liposomes. 
J Parenter Sci Technol. 1991;45(3):124-7. 
79. Loukas YL, Jayasekera P, Gregoriadis G. Novel liposome-based multicomponent 
systems for the protection of photolabile agents. Int J Pharm. 1995;117(1):85-94. 
80. Sue-Chu M, Kristensen S, Tønnesen HH. Photoinduced color changes in two different 
qualities of riboflavin in the solid state and in various tablet formulations. Photoreactivity of 
biologically active compounds. XX. Pharmazie. 2009;64(7):428-35. 
81. Sue-Chu M, Kristensen S, Tønnesen HH. Influence of lag-time between light exposure 
and color evaluation of riboflavin in the solid state. Pharmazie. 2008;63(7):545-6. 
82. Heelis PF. The photophysical and photochemical properties of flavins (isoalloxazines). 
Chem Soc Rev. 1982;11(1):15-39. 
83. Müller F. Chemistry and biochemistry of flavoenzymes, vol. 1–3. Boca Raton, USA: 
CRC Press; 1992. 
84. Hemmerich P, Knappe W-R, Kramer HEA, Traber R. Distinction of 2e- and 1e- 
reduction modes of the flavin chromophore as studied by flash photolysis. Eur J Biochem. 
1980;104(2):511-20. 
85. Priyadarsini KI. Photophysics, photochemistry and photobiology of curcumin: studies 
from organic solutions, bio-mimetics and living cells. J Photochem Photobiol, C. 
2009;10(2):81-95. 
86. Haukvik T, Bruzell E, Kristensen S, Tønnesen HH. Photokilling of bacteria by 
curcumin in selected polyethylene glycol 400 (PEG 400) preparations: studies on curcumin 
and curcuminoids, XLI. Pharmazie. 2010;65(8):600-6. 
87. Dovigo LN, Pavarina AC, Carmello JC, Machado AL, Brunetti IL, Bagnato VS. 
Susceptibility of clinical isolates of Candida to photodynamic effects of curcumin. Lasers 
Surg Med. 2011;43(9):927-34. 
61 
 
88. Ribeiro APD, Pavarina AC, Dovigo LN, Brunetti IL, Bagnato VS, Vergani CE, et al. 
Phototoxic effect of curcumin on methicillin-resistant Staphylococcus aureus and L929 
fibroblasts. Lasers Med Sci. 2013;28(2):391-8. 
89. Dovigo LN, Pavarina AC, Ribeiro APD, Brunetti IL, Costa CAdS, Jacomassi DP, et al. 
Investigation of the photodynamic effects of curcumin against Candida albicans. Photochem 
Photobiol. 2011;87(4):895-903. 
90. Dovigo LN, Carmello JC, Costa CAdS, Vergani CE, Brunetti IL, Bagnato VS, et al. 
Curcumin-mediated photodynamic inactivation of Candida albicans in a murine model of 
oral candidiasis. Med Mycol. 2013;51(3):243-51. 
91. Hegge AB, Nielsen TT, Larsen KL, Bruzell E, Tønnesen HH. Impact of curcumin 
supersaturation in antibacterial photodynamic therapy - effect of cyclodextrin type and 
amount: studies on curcumin and curcuminoides XLV. J Pharm Sci. 2012;101(4):1524-37. 
92. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "curcumin": from kitchen to 
clinic. Biochem Pharmacol. 2008;75(4):787-809. 
93. Pabon HJJ. Synthesis of curcumin and related compounds. Recl Trav Chim Pays-Bas. 
1964;83(4):379-86. 
94. Tønnesen HH, Masson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. 
Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm. 
2002;244(1-2):127-35. 
95. Tønnesen HH, Karlsen J. Alkaline degradation of curcumin: studies on curcumin and 
curcuminoids V. Z Lebensm-Unters Forsch. 1985;180(2):132-4. 
96. Nardo L, Paderno R, Andreoni A, Masson M, Haukvik T, Tønnesen HH. Role of H-
bond formation in the photoreactivity of curcumin. Spectroscopy. 2008;22(2,3):187-98. 
97. Tønnesen HH, Karlsen J, van Henegouwen GB. Photochemical stability of curcumin:  
studies on curcumin and curcuminoids VIII. Z Lebensm Unters Forsch. 1986;183(2):116-22. 
98. Singh R, Kristensen S, Tønnesen HH. Influence of vehicle properties and excipients 
on hydrolytic and photochemical stability of curcumin in preparations containing pluronics: 
studies of curcumin and curcuminoids XLVIII. Pharmazie. 2013;68(3):160-9. 
62 
 
99. Tomren MA, Masson M, Loftsson T, Tønnesen HH. Symmetric and asymmetric 
curcuminoids: stability, activity and complexation with cyclodextrins: studies on curcumin 
and curcuminoids XXXI. Int J Pharm. 2007;338(1-2):27-34. 
100. Tønnesen HH. Solubility, chemical and photochemical stability of curcumin in 
surfactant solutions: studies of curcumin and curcuminoids, XXVIII. Pharmazie. 
2002;57(12):820-4. 
101. Dahl TA, McGowan WM, Shand MA, Srinivasan VS. Photokilling of bacteria by the 
natural dye curcumin. Arch Microbiol. 1989;151(2):183-5. 
102. Singh R, Tønnesen HH, Kristensen S, Berg K. The influence of Pluronics on dark 
cytotoxicity, photocytotoxicity, localization and uptake of curcumin in cancer cells: studies on 
curcumin and curcuminoids XLIX. Photochem Photobiol Sci. 2013;12(3):559-75. 
103. Tøennesen HH, de Vries H, Karlsen J, Beijersbergen van Henegouwen G. 
Investigation of the photobiological activity of curcumin using bacterial indicator systems: 
studies on curcumin and curcuminoids IX. J Pharm Sci. 1987;76(5):371-3. 
104. Park K, Lee J-H. Photosensitizer effect of curcumin on UVB-irradiated HaCaT cells 
through activation of caspase pathways. Oncol Rep. 2007;17(3):537-40. 
105. Chignell CF, Bilski P, Reszka KJ, Motten AG, Sik RH, Dahl TA. Spectral and 
photochemical properties of curcumin. Photochem Photobiol. 1994;59(3):295-302. 
106. Haukvik T. Curcumin as a photosensitizer in antimicrobial photodynamic therapy: 
influence of formulation and molecular structure modification. Oslo, Norway: University of 
Oslo; 2012. 
107. Jiang Y, Leung AW, Hua H, Rao X, Xu C. Photodynamic action of LED-activated 
curcumin against Staphylococcus aureus involving intracellular ROS increase and membrane 
damage. Int J Photoenergy. 2014:637601/1-/8. 
108. Bulit F, Grad I, Manoil D, Filieri A, Simon S, Wataha JC, et al. Antimicrobial activity 
and cytotoxicity of 3 photosensitizers activated with blue light. J Endod. 2014;40(3):427-31. 
63 
 
109. Leite DPV, Paolillo FR, Parmesano TN, Fontana CR, Bagnato VS. Effects of 
photodynamic therapy with blue light and curcumin as mouth rinse for oral disinfection: a 
randomized controlled trial. Photomed Laser Surg. 2014;32(11):627-32. 
110. Araujo NC, Fontana CR, Gerbi MEM, Bagnato VS. Overall-mouth disinfection by 
photodynamic therapy using curcumin. Photomed Laser Surg. 2012;30(2):96-101. 
111. Singh R. Investigation and development of aqueous curcumin preparations for 
photodynamic therapy by use of nanovehicles. Oslo, Norway: Univeristy of Oslo; 2013. 
112. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in 
laboratory studies and clinical trials. Antioxid Redox Signaling. 2008;10(3):511-46. 
113. Wegiel LA, Zhao Y, Mauer LJ, Edgar KJ, Taylor LS. Curcumin amorphous solid 
dispersions: the influence of intra and intermolecular bonding on physical stability. Pharm 
Dev Technol. 2014;19(8):976-86. 
114. Sanphui P, Goud NR, Khandavilli UBR, Bhanoth S, Nangia A. New polymorphs of 
curcumin. Chem Commun. 2011;47(17):5013-5. 
115. Hilfiker R, editor. Polymorphism: In the pharmaceutical industry. Weinheim, 
Germany: Wiley-VCH Verlag; 2006.  
116. Gloor A, inventor; DSM IP Assets B. V., Neth., assignee. Process for the purification 
of riboflavin. Patent WO2005014594A1. 2005. 
117. Mohnicke M. On the control of riboflavin (vitamin B2) crystal structures.  Aachen, 
Germany:  Shaker Verlag; 2007. 
118. van Drooge DJ, Hinrichs WLJ, Visser MR, Frijlink HW. Characterization of the 
molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using 
differential scanning calorimetry and gravimetric water vapour sorption techniques. Int J 
Pharm. 2006;310(1-2):220-9. 
119. Repka MA, Battu SK, Upadhye SB, Thumma S, Crowley MM, Zhang F, et al. 
Pharmaceutical applications of hot-melt extrusion: Part II. Drug Dev Ind Pharm. 
2007;33(10):1043-57. 
64 
 
120. Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Battu SK, et al. 
Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev Ind Pharm. 
2007;33(9):909-26. 
121. Van Eerdenbrugh B, Baird JA, Taylor LS. Crystallization tendency of active 
pharmaceutical ingredients following rapid solvent evaporation-classification and comparison 
with crystallization tendency from undercooled melts. J Pharm Sci. 2010;99(9):3826-38. 
122. Hegge AB, Masson M, Kristensen S, Tøennesen HH. Investigation of curcumin-
cyclodextrin inclusion complexation in aqueous solutions containing various alcoholic co-
solvents and alginates using an UV-VIS titration method: studies of curcumin and 
curcuminoides XXXV. Pharmazie. 2009;64(6):382-9. 
123. Alexandridis P, Alan Hatton T. Poly(ethylene oxide)-poly(propylene oxide)-
poly(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: 
thermodynamics, structure, dynamics, and modeling. Colloids Surf, A. 1995;96(1/2):1-46. 
124. Ebitani M, Kashiwagi H, Inoue M, Nishibe K. Preparation, stability, and compositions 
of the crystals of reduced riboflavins. Bull Chem Soc Jpn. 1991;64(4):1093-6. 
125. Mueller F, Hemmerich P, Ehrenberg A, Palmer G, Massey V. Chemical and electronic 
structure of the neutral flavin radical as revealed by electron spin resonance spectroscopy of 
chemically and isotopically substituted derivatives. Eur J Biochem. 1970;14(1):185-96. 
126. Penzkofer A. Reduction-oxidation photocycle dynamics of flavins in starch films. Int J 
Mol Sci. 2012;13:9157-83. 
127. Ramamurthy V, Venkatesan K. Photochemical reactions of organic crystals. Chem 
Rev. 1987;87(2):433-81. 
128. Mandal S, Banerjee C, Ghosh S, Kuchlyan J, Sarkar N. Modulation of the 
photophysical properties of curcumin in nonionic surfactant (Tween® 20) forming micelles 
and niosomes: a comparative study of different microenvironments. J Phys Chem B. 
2013;117(23):6957-68. 
129. Ghosh S, Kuchlyan J, Banik D, Kundu N, Roy A, Banerjee C, et al. Organic additive, 
5-methylsalicylic acid induces spontaneous structural transformation of aqueous Pluronic 
65 
 
triblock copolymer solution: a spectroscopic investigation of interaction of curcumin with 
Pluronic micellar and vesicular aggregates. J Phys Chem B. 2014. 
130. Baglole KN, Boland PG, Wagner BD. Fluorescence enhancement of curcumin upon 
inclusion into parent and modified cyclodextrins. J Photochem Photobiol, A. 
2005;173(3):230-7. 
131. Raghavan SL, Trividic A, Davis AF, Hadgraft J. Crystallization of hydrocortisone 
acetate: influence of polymers. Int J Pharm. 2001;212(2):213-21. 
132. Gao P, Akrami A, Alvarez F, Hu J, Li L, Ma C, et al. Characterization and 
optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) 
for improved oral absorption. J Pharm Sci. 2009;98(2):516-28. 
133. Overhoff KA, McConville JT, Yang W, Johnston KP, Peters JI, Williams RO, III. 
Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption 
of tacrolimus made by ultra-rapid freezing. Pharm Res. 2008;25(1):167-75. 
134. Dai W-G, Dong LC, Li S, Deng Z. Combination of Pluronic/vitamin E TPGS as a 
potential inhibitor of drug precipitation. Int J Pharm. 2008;355(1-2):31-7. 
135. Mackellar AJ, Buckton G, Newton JM, Orr CA. The controlled crystallization of a 
model powder: 2. Investigation into the mechanism of action of poloxamers in changing 
crystal properties. Int J Pharm. 1994;112(1):79-85. 
136. Samanta S, Roccatano D. Interaction of curcumin with PEO-PPO-PEO block 
copolymers: a molecular dynamics study. J Phys Chem B. 2013;117(11):3250-7. 
137. Kurkov SV, Loftsson T. Cyclodextrins. Int J Pharm. 2013;453(1):167-80. 
138. Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from 
micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst. 
2002;19(1):1-72. 
139. Winter S, Tortik N, Kubin A, Krammer B, Plaetzer K. Back to the roots: 
photodynamic inactivation of bacteria based on water-soluble curcumin bound to 
polyvinylpyrrolidone as a photosensitizer. Photochem Photobiol Sci. 2013;12(10):1795-802. 
66 
 
140. Williams AC, Barry BW. Penetration enhancers. Adv Drug Delivery Rev. 
2004;56(5):603-18. 
141. Hegge AB, Bruzell E, Kristensen S, Tønnesen HH. Photoinactivation of 
Staphylococcus epidermidis biofilms and suspensions by the hydrophobic photosensitizer 
curcumin - Effect of selected nanocarrier. Eur J Pharm Sci. 2012;47(1):65-74. 
142. Bonilla CA. Human mixed saliva protein concentration. J Dent Res. 1972;51(2)(Pt. 
2):664. 
143. Moseley R, Hilton JR, Waddington RJ, Harding KG, Stephens P, Thomas DW. 
Comparison of oxidative stress biomarker profiles between acute and chronic wound 
environments. Wound Repair Regen. 2004;12(4):419-29. 
144. Zsila F, Bikadi Z, Simonyi M. Unique, pH-dependent biphasic band shape of the 
visible circular dichroism of curcumin-serum albumin complex. Biochem Biophys Res 
Commun. 2003;301(3):776-82. 
145. Mandeville J-S, Froehlich E, Tajmir-Riahi HA. Study of curcumin and genistein 
interactions with human serum albumin. J Pharm Biomed Anal. 2009;49(2):468-74. 
146. Reddy ACP, Sudharshan E, Rao AGA, Lokesh BR. Interaction of curcumin with 
human serum albumin-a spectroscopic study. Lipids. 1999;34(10):1025-9. 
147. Mohammadi F, Bordbar A-K, Divsalar A, Mohammadi K, Saboury AA. Analysis of 
binding interaction of curcumin and diacetylcurcumin with human and bovine serum albumin 
using fluorescence and circular dichroism spectroscopy. Protein J. 2009;28(3-4):189-96. 
 
 
 
 
